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Methamphetamine is a highly addictive stimulant drug whose illicit use and resultant addiction 
has become an alarming global phenomenon. The mesolimbic dopaminergic system in the brain, 
originating in the ventral tegmental area and terminating in the nucleus accumbens, has been 
shown to be central to the neurobiology of addiction and the establishment of addictive 
behaviour. This pathway, as part of the reward system of the brain, has also been shown to be 
important in classical conditioning, which is a learnt response. This common pathway has 
supported theories suggesting addiction as a case of maladaptive associative learning. Within the 
modulation of learning and memory, the neurohypophyseal hormones vasopressin and oxytocin 
have been seen to play a vital role. Vasopressin exerts a long- term facilitatory effect on learning 
and memory processes. Studies have shown that the stress responsive AVP V1b receptor systems 
are a critical component of the neural circuitry underlying emotional consequences of drug 
reward. Oxytocin, on the other hand, has an effect on learning and memory opposite to that of 
vasopressin. Previous studies have shown that oxytocin caused a decrease in heroin self-
administration, as well as attenuated the appearance of cocaine-induced hyperactivity and 
stereotyped behaviour. Therefore, we adopted a reinstatement conditioned place preference 
model to investigate whether a V1b antagonist or oxytocin treatment would cause a decrease in 
methamphetamine seeking behaviour. Behavioural findings indicated that methamphetamine 
induced a change in the place preference in the majority of our animals. This change in 
preference was not seen after vasopressin administration in the extinction phase. On the other 
hand, the change in place preference was enhanced during the reinstatement phase in the animals 
treated with oxytocin. Striatal dopamine levels were determined, as methamphetamine is known 
to increase dopamine transmission in this area. Results showed that rats that received both 
methamphetamine and oxytocin had significantly higher striatal dopamine than those that 
received oxytocin alone. Western blot analysis for hippocampal cyclic AMP response element 
binding protein (CREB) was also conducted as a possible indicator of glutamatergic NMDA 
receptor activity, a pathway that is important for learning and memory. The Western blot 
analysis showed no changes in hippocampal pCREB expression. Overall our data led us to 
conclude that methamphetamine treatment can change place preference behaviour in rats and that 




Drug addiction is a global problem causing physical, emotional and social harm, both to those 
addicted and those around them (Buxton and Dove, 2008). South Africa is not excluded from 
this statistic, with continuing escalation in the use of illicit drugs especially between the ages 
of 15 – 25 years being reported by the South African Community Epidemiology Network on 
Drug Use (SACENDU Report June 2011). In recent years, the abuse of methamphetamine in 
South Africa has increased, with reports from the United Nations Office on Drugs and Crime 
(UNODC) indicating that of the 16,300 people who sought treatment for drug abuse in South 
Africa in 2006, 26.9% were for methamphetamines. This makes methamphetamine one of the 
highest abused drugs nationally, second only to cannabis at 32.7%.  
Within the paradigm of addiction many theories exist, some of which will be expanded upon 
in the literature review in chapter 1. However, much focus has been centred on addiction as a 
learnt response, with theories suggesting addiction as a case of maladaptive associative 
learning (Kelly and Berridge, 2002; Chao et al., 2004; Vanderschuren and Everitt, 2005; 
Feltenstein and See, 2008). Within learning and memory, the process of long-term 
potentiation has been shown to play a vital role, involving the activation of cyclic adenosine 
monophospate response element binding protein (CREB) to initiate memory storage (Silva et 
al., 1998). This process will be discussed in more detail in chapter 1.  
Regardless of the theory, one common characteristic is seen with regards to addiction, and 
that is that drugs of abuse all act on a specific pathway in the brain known as the mesolimbic 
pathway (Leff et al., 2000). This pathway is mediated by the neurotransmitter dopamine, 
which is elevated in response to all drugs of abuse, including methamphetamines (Volkow et 
al., 2003). In the literature review of this dissertation, dopamine, methamphetamine and the 
relationship between the two will be discussed.  
Neurohormones vasopressin and oxytocin play vital roles both peripherally as well as 
centrally, with its role in learning and memory being subject to much debate (Kovács et al., 
1979; Sahgal et al., 1984; Van Ree et al., 1985; Engelmann et al., 1996; De Wied, 1997; 
Boccia et al., 1998; Heinrichs et al., 2004). The general consensus is that vasopressin has a 
stimulatory effect of learning and memory, while oxytocin has an inhibitory effect (Heinrichs 
et al., 2004; Ring, 2005). The peripheral and central effects of both these neurohormones and 
their roles in learning and memory will be detailed in the literature review that follows. 
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With addiction being viewed as a learnt behaviour, and the suggested roles of neurohormones 
in learning and memory, the limited interest in the role of vasopressin and oxytocin in 
addiction is surprising. The few studies that have been conducted in this regard have been 
inconclusive and none has focused on methamphetamine addiction. 
To address this shortcoming in our current knowledge we investigated the effects of 
vasopressin and oxytocin in an animal model of methamphetamine-induced addictive 
behaviour. In doing so we developed a 3 stage place preference model of addiction, 
comprising of acquisition, extinction and reinstatement. This model will be explained in more 
detail in chapter 2 of this dissertation, where an article outlining our research is included.  
Given the opposite effects of vasopressin and oxytocin on learning and memory, we used a 
vasopressin V1b antagonist (SSR 149415) and oxytocin as treatment methods in the 
extinction phase. Our hypothesis was that administration of the vasopressin antagonist and 
oxytocin would reverse the associative learning developed in the place preference model, and 
result in a decrease in addictive behaviour when presented with drug cues in the reinstatement 
phase.  
As a measure of construct validity, dopamine levels were evaluated in the striatum of 
methamphetamine - treated rats and controls. Similarly, CREB levels were assessed in the 
hippocampal tissue to determine if signalling processes within learning and memory 
pathways were affected in any of the rat groups. Methodology for these neurochemical 
analyses is outlined in chapter 2 of this dissertation.  
Finally our findings are reported and discussed in the article contained in this dissertation, 
and are summarized in chapter 3 with recommendations for future research in this area. 
The Animal Ethics Subcommittee of the University of KwaZulu-Natal approved all 
procedures, which were all in accordance to the guidelines of the National Institutes of Health 








1.1 Addiction  
Drug addiction is a chronically relapsing disorder that is characterized by a compulsion to 
take a drug, a lack of control in limiting this intake despite knowledge of the negative 
consequences, and the withdrawal of the drug resulting in the emergence of a negative 
emotional state and motivation signs of discomfort (Roberts and Koob, 1997; Heather, 1998; 
Koob, 2000; Hyman and Malenka, 2001; Shippenberg and Koob, 2002; Vanderschuren and 
Everitt, 2005; Feltenstein and See, 2008; Koob and Volkow, 2010).  
1.1.1 Theories of addiction 
Numerous theories have been proposed as to the mechanism by which addiction develops and 
is maintained. A few of the more prominent theories will be discussed below;  
1.1.1.1 Hedonic theory:  
This theory postulates that addiction develops in relation to positive and negative reinforcing 
properties of a drug (Chao et al., 2004; Feltenstein and See, 2008). The basic principle is that 
initial consumption of the drug results in the production of positive effects (e.g. euphoria, 
pleasure) or reward, which may drive subsequent drug administration in order to re-
experience the reward again (positive reinforcement) (Kelly and Berridge, 2002; Chao et al., 
2004; Feltenstein and See, 2008).  
This positive reinforcement accounts for the initiation of drug taking behaviour, but the 
recurrent drive for reward is also mediated by the appearance of withdrawal symptoms 
(anhedonia and dysphoria) when drug use ceases (Kelly and Berridge, 2002; Chao et al., 
2004; Feltenstein and See, 2008). Thus the need to alleviate these negative effects may result 
in continued drug use and may account for the transition from social use or experimentation 
to compulsive behaviour (Chao et al., 2004).  
These opposing processes of euphoria and dysphoria are measured on a hedonic scale, and 
make up the components of the opponent process theory (Chao et al., 2004).  Continued 
exposure to the abused drug will result in a rise in the hedonic set point which results in a 
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decreased hedonistic effect of the drug at a constant dose while increasing the intensity of 
withdrawal symptoms (Chao et al., 2004; Feltenstein and See, 2008). This shift from a 
positive to a negative hedonistic state and the dysregulation of brain reward systems leads to 
a loss of control over drug intake and increased vulnerability to relapse (Chao et al., 2004; 
Vanderschuren and Everitt, 2005; Feltenstein and See, 2008).   
Whilst the hedonic theory provides a mechanism for the initiation and maintenance of 
compulsive drug use, it fails to account for other aspects of drug abuse, such as a relapse into 
drug seeking and drug taking behaviour following prolonged periods of abstinence, when 
overt withdrawal symptoms are no longer present (Chao et al., 2004; Feltenstein and See, 
2008). Nor does it explain the addictive nature of psychostimulant drugs, who present no 
physical, and variable and mild emotional withdrawal symptoms; or the fact that many non-
addictive drugs may present severe withdrawal symptoms on cessation of use (Hyman and 
Malenka, 2001). 
1.1.1.2 Incentive-sensitization:  
The neural link between the ventral tegmental area (VTA) and the nucleus accumbens (NAc) 
plays a role in attributing salience to a stimulus, i.e. it’s perceived value or attractiveness 
(Vanderschuren and Everitt, 2005). This theory suggests that repeated exposure to drugs of 
abuse leads to adaptations which results in the sensitization of this neural circuitry to the drug 
and drug-related stimuli (Hymen et al., 2001; Kelly and Berridge, 2002; Vanderschuren and 
Everitt, 2005; Feltenstein and See, 2008 ).  This sensitization causes the excessive attribution 
of incentive salience to the drug and associated stimuli, causing a shift from drug ‘liking’ to 
them being excessively ‘wanted’ and may drive compulsive drug-seeking, drug taking and 
relapse behaviours (Kelly and Berridge, 2002; Wolf, 2002; Chao et al., 2004; Vanderschuren 
and Everitt, 2005; Feltenstein and See, 2008).  This theory distinguishes the important 
difference between drug ‘liking’ and drug ‘wanting’, which separates the euphoric power of 
the drug from its addictive potential, i.e. drug self-administration can be maintained even in 
the absence of pleasure (Chao et al., 2004; Saah, 2005; Adinoff, 2007).  
1.1.1.3 Stimulus-Response (S-R) habit learning:  
Repeated exposure to drugs results in alterations in the cellular mechanism of associated S-R 
learning and reward predictions, with drug seeking being triggered by drug associated cues 
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(Kelly and Berridge, 2002; Chao et al., 2004; Vanderschuren and Everitt, 2005; Everitt et al., 
2008). Accordingly, it can be said that drug taking is a learned response to conditional stimuli 
that results in deeply ingrained drug habits beyond the control of the addicted individual 
(Kelly and Berridge, 2002; Chao et al., 2004; Vanderschuren and Everitt, 2005; Feltenstein 
and See, 2008).   
1.1.1.4 Frontal cortex dysfunction: 
Another theory of addiction that may explain its persistent nature outlines dysfunctions 
within the pre-frontal cortex in response to prolonged drug exposure (Vanderschuren and 
Everitt, 2005; Feltenstein and See, 2008).  This reduction in PFC activity reduces its 
inhibitory control over behaviour and decision making skills, impairing the ability of the drug 
user to inhibit inappropriate drug-centred behaviour, and allowing drug-associated behaviours 
to become dominant (Vanderschuren and Everitt, 2005; Feltenstein and See, 2008).   
It is possible that a combination of all the factors suggested in these theories contribute to the 
neural and behavioural pathologies seen in addiction (Chao et al., 2004) 
1.1.2 Learning and Memory in Addiction 
Drugs of abuse are both rewarding, in that they are interpreted by the brain as being positive, 
as well as reinforcing, meaning that behaviours that are associated with drug use tend to be 
repeated (Kopnisky and Hyman, 2002). This persistence of drug taking behaviour is due to 
the drugs ability to induce long-term neuroadaptations on a structural, cellular, molecular and 
genomic level (Kelly and Berridge, 2002; Kopnisky and Hyman, 2002).  
These molecular and cellular adaptations seen in addiction have also been implicated in the 
processes of learning and memory, indicating a shared mechanism between the two (Nestler, 
2001; Winger et al., 2005). The relationship between addiction and learning and memory is 
further supported by some key behavioural features of addiction that have been described as 
forms of memory (Nestler, 2001; Kopnisky and Hyman, 2002; Hyman, 2006). One of these 
core features is the conditioned aspects of addiction, which occurs due to the inappropriate 
recruitment of neuronal circuits and molecular mechanisms usually involved in associative 
learning (Nestler, 2001; Kopnisky and Hyman, 2002; Hyman, 2006). All drugs of abuse 
increase dopamine levels in the mesocorticolimbic system of the brain, and it is this 
dopamine that promotes the learning of new associations between the drug and the  
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environment (Kalivas and O’ Brien, 2008). The role of associative learning also becomes 
evident during late relapse, where exposure to cues that were associated with drugs and drug 
use, are able to induce drug taking and relapse after a period of abstinence (Berke and 
Hyman, 2000; Nestler, 2001; Kopnisky and Hyman, 2002; Wolf, 2002; Saal and Malenka, 
2005; Hyman, 2006). These cues may be external factors, such as the people, places or things 
associated with prior drug use, or internal factors such as emotions, bodily feelings or 
withdrawal symptoms (Berke and Hyman, 2000; Hyman, 2006). Dopamine acts within the 
relapse paradigm, reinforcing the prior learnt associations and cueing the drug user to carry 
out drug seeking behaviour (Kalivas and O’ Brien, 2008).  
1.1.3 Neural circuits in addiction  
The neural circuitry involved in the neurobiology of addiction fall broadly into four 
categories, namely; reward/salience, motivation/drive, learning/conditioning and inhibitory 
control/emotional regulation/executive function (Volkow et al., 2008). Any disruption within 
these four circuits results in the enhanced value of a reinforcer, in this case drugs, over other 
reinforcers; such a natural rewards e.g. food, sex (Hyman, 2006; Volkow et al., 2008). This 
overvaluing of drug reward over natural reward contributes to compulsive drug use, as well 
as the marked narrowing of an addict’s life goals to be focused on obtaining and using drugs 
(Saal and Malenka, 2005; Hyman, 2006).   
The learning/conditioning circuit within the brain, when exposed repeatedly to drugs of 
abuse, result in the formation of new linked memories, a process which is mediated by the 
hippocampus and the amygdala (Volkow et al., 2008). Learning and memory becomes 
encoded via the usage of interneuronal connections, with synapses that experience frequent 
use being strengthened and vice versa, and the stability of these changes determining the 
presence of a stored memory (Wolf, 2002; Fanselow et al., 2005). Therefore, experience, 
such as repeated drug exposure, may result in a strengthened communication between 
neurons in the learning pathways in the brain, resulting in the long-term storage of a memory 
(Wolf, 2002). These linked-memories condition the drug user to anticipate pleasurable 
responses not only from the drug itself, but from any stimulus conditioned or associated with 
the drug (Volkow et al., 2008). This stimulus-response behaviour triggers and maintains the 
automatic habit responses and seeking behaviours that drive relapse in drug addicts (Everitt et 
al., 2008; Volkow et al., 2008).  
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Synaptic plasticity is proposed to be the mechanism that underlies the formation of these 
associative learning behaviours, and involves (i) changes in the strength of existing neural 
connections, (ii) the formation, (iii) elimination and/or (iv) remodelling of dendrite-axon 
structures (Fanselow et al., 2005; Saal and Malenka, 2005; Hyman 2006). These changes 
occur via altered gene and protein expression within neurons that receive an enhanced or 
diminished signal, and produce long-term changes in neural circuits which result in long 
lasting alterations in behaviours (Hyman, 2006). Synaptic plasticity therefore may have an 
important role in mediating the behavioural consequences of drug use and the development of 
addiction (Thomas and Malenka, 2003).  
1.1.4 The role of LTP and LTD in addiction 
Long-term potentiation (LTP) and long-term depression (LTD) are mechanisms underlying 
synaptic plasticity that bring about neuronal changes, with LTP responding to enhanced 
signaling to produce changes which increase synaptic strength, while LTD responds to 
diminished signalling to produce changes which decrease synaptic strength (Saal and 
Malenka, 2005; Hyman, 2006). LTP and LTD are demonstrated in all excitatory synapses 
within the mammalian brain however, the mechanisms by which they occur differ in different 
brain regions (Hyman and Malenka, 2001).  
LTP as a potential cellular mechanism for learning and memory has been well established 
within the hippocampus (Mizuno et al., 2002; Wolf, 2002). In the CA1 region each excitatory 
synapse contains two glutamate receptor subtypes, namely α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) and N-Methyl-D-aspartate (NMDA) receptors, whose 
interactions with glutamate to establish LTP and LTD have been implicated in the process of 
addiction (Figure 1, Nestler, 2001; Mizuno et al., 2002; Saal and Malenka, 2005). 
When glutamate released from the presynaptic neuron is bound to the AMPA receptor, the 
receptor channels allow an influx of sodium ions into the post-synaptic neuron, causing the 
neuron to become depolarized and more likely to fire action potentials (Figure 1, Saal and 
Malenka, 2005). This depolarization enables the expulsion of a magnesium ion that sits in the 
pore of the NMDA receptor channel. Interestingly, even with glutamate binding promoting 
the opening of NMDA receptor, ions will not flow into the neuron until the magnesium is 













Figure 1: Long-term potentiation signalling pathway 
 
Thus, NMDA activation is responsible for the induction of LTP, but can only occur due to 
high levels of synaptic activity and depolarization of the post-synaptic membrane, which is 
brought about by the activation of AMPA receptors (Bliss and Collingridge, 1993; Hyman 
and Malenka, 2001; Thomas and Malenka, 2003; Fanselow et al., 2005; Saal and Malenka, 
2005). 
NMDA receptors channels are highly permeable to calcium ions and the influx of calcium
 
into the post-synaptic neuron is the critical trigger for both LTP and LTD (Figure 1, Wolf, 
2002; Fanselow et al., 2005; Saal and Malenka, 2005). The triggering of LTP or LTD is 
dependent upon the amount of calcium that enters the post-synaptic cells, with different 
amounts activating intracellular second messenger pathways which will either increase (in the 
case of LTP) or decrease (in the case of LTD) synaptic strength of the NMDA containing 
neuron (Fanselow et al., 2005; Saal and Malenka, 2005). LTP results from a large amount of 
calcium entering the neuron, which subsequently activates protein kinases, with the critical 
one being Calcium/calmodulin-dependent protein kinases II (CaMKII), while LTD is caused 




calcium/calmodulin-dependant protein phosphatase calcineurin (phosphatases 2B) and 
protein phosphatases 1 (Wolf, 2002; Saal and Malenka, 2005).  
LTP induced changes at the glutamate synapses include; an increase in neurotransmitter 
release per action potential at the presynaptic neuron, the insertion of more AMPA receptors 
onto the membrane as well as causing the postsynaptic cells more responsive to glutamate, 
which will aid in mediating the excitatory transmission of glutamate, and an increase in 
synaptic contacts via the growth of new dendritic spines, while LTD causes the removal of 
AMPA receptors from the synapse (Figure 1, Wolf, 2002; Fanselow et al., 2005; Saal and 
Malenka, 2005). 
As it is well known that LTP and LTD play critical roles in the neuroadaptations that mediate 
all forms of experience-dependent plasticity, it is likely that they are also the mechanisms by 
which drugs of abuse induce alterations in neural circuitry (Hyman and Malenka, 2001; 
Thomas and Malenka, 2003; Saal and Malenka, 2005; Hyman, 2006). In fact, there is ample 
evidence that LTP/LTD-like changes occur within the mesolimbic system in response to 
drugs of abuse, and so alter the networks related to motivation and reward (Hyman and 
Malenka, 2001; Wolf, 2002; Saal and Malenka, 2005). 
1.1.5 LTP-associated signaling pathways 
LTP and learning within the hippocampus results in the downstream activation of cyclic 
adenosine monophosphate (cAMP) and cAMP response element-binding protein (CREB) 
mediated transcription, a pathway whose upregulation is one of the best established 
adaptations to chronic exposure to drugs of abuse (Figure 1, Nestler, 2001; Kopnisky and 
Hyman, 2002; Chao et al., 2004).   
CREB acts as an important transcription factor and regulates gene expression in learning and 
memory circuits via the cAMP pathway (Nestler, 2001; Mizuno et al., 2002; Fanselow et al., 
2005; Hyman, 2006). CREB-mediated transcription may only occur once CREB has been 
activated by its phosphorylation at Ser133, which in turn may be induced by a number of 
transduction cascades, including; the cAMP pathway via protein kinase A (PKA), 
intracellular calcium via CaMK, the Ras/extracellular signal regulated kinase (ERK) protein 
kinase pathway, the phosphatidylinositol-3-kinase (PI3K)/Akt kinase pathways and stress 
induced signaling cascades (Nestler, 2001; Mizuno et al., 2002; Chao et al., 2004; Hyman, 
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2006). CREB therefore appears to be a final common denominator of various signaling 
pathways whose activation may result from a variety of external and/or internal stimuli. 
CREB regulates the transcription of genes which contain a cAMP response element (CRE) 
site within their regulatory region, which have been identified in numerous genes found 
within the nervous system. Such genes include those that encode for neuropeptides, 
neurotransmitters, signaling proteins and other transcription factors (Nestler, 2001; Hyman, 
2006).  
A consequence of repeated drug exposure is the altering of the transcription of specific target 
genes via repeated disruption to intracellular signal transduction pathways, causing altered 
gene expression and ultimately changes within the neural circuitry that result in behavioural 
changes (Nestler, 2001). Interestingly, CREB activity and the expression of the genes that are 
regulated by CREB, are greatly enhanced in response to the repeated exposure to drugs of 
abuse, with an increase in CREB phosphorylation seen in reward related areas of the brain 
such as the VTA, the amygdala and the frontal cortex (Hyman and Malenka, 2001; Hyman, 
2006). It has been postulated that this phosphorylation of CREB may be one of the pivotal 
molecular mechanisms behind drug-induced LTP (Hyman, 2006).  
CREB therefore plays an important role in the establishment of learning and memory and 
since the administration of drugs of abuse produces an increase in CREB levels (Hyman, 
2005), its function in the development of addictive behaviour justifies further investigation.  
1.1.6 Treatment of Addiction 
1.1.6.1 Principles of Addiction Treatment  
Drug addiction or dependence and its development is a complex process involving both 
individual vulnerability due to pschychological and biological factors, as well as 
environmental factors such as sociocultural and economic status (Anglin and Hser, 1990; O’ 
Brien, 2003). There is therefore no simple cure for addiction, which develops as a chronic 
condition, and its treatment should therefore be seen as a long term venture, in the same vein 
as those for hypertension and diabetes (Anglin and Hser, 1990; O’ Brien, 2003).  
In order to develop an effective treatment program, it is important to assess the cause of the 
drug abuse and impliment the appropriate intervention (Anglin and Hser, 1990; Leshner, 
1999). Treatment approaches are varied depending on what its underlying cause is perceived 
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to be by the treatment provider (Anglin and Hser, 1990). Treatment programs which view 
addiction as a sign of moral weakness in a person may model their interventions in the form 
of punishment, incarceration or moral education, while programs viewing addiction as a 
chronic disease will emphasize the importance of medications and therapeutic and 
behavioural management of the patient (Anglin and Hser, 1990).  
Other factors to which addiction have been attributed are patterns of maladaptive learning of 
a habit or underlying psychiatric illness such as depression or schizophrenia, where the 
patient is essentially trying to treat their illness by using addictive drugs (Anglin and Hser, 
1990; Leshner, 1999). In both these cases, treatment programs adopt a drug free paradigm 
and instead focus on treating the underlying cause of the addiction by utilising psychotherapy 
and cognitive and behavioural management techniques (Anglin and Hser, 1990; Leshner, 
1999).  
Regardless of modality-specific treatment approaches, all programs consider four main 
outcome goals in the treatment of addiction:- 1. the reduction or cessation of drug or alcohol 
use 2. improving the personal health (including medical and psychiatric health) and the 
quality of life of the patient 3. improving social functioning of the patient in terms of family 
and social relationships and employment, as part of relapse prevention strategies, and 4. 
reducing behaviours that may lead to the spread of infectious disease or the perpetration of 
crime that may be a threat to the public (Anglin and Hser, 1990; McLellan et al., 2000).  
In the interest of achieving these goals, addiction treatment generally begins with a medical 
and psychosocial assessment of the patient, and thereafter helping to alleviate the acute 
physical withdrawal symptoms and detoxify the patient to aid in bringing them to a drug free 
state (Leshner, 1999; O’Brien, 2003; Yahyavi-Firouz-Abadi and See, 2009). Secondary to the 
initial detoxification, which alone does not have much therapeutic value, relapse prevention is 
the next important step in addiction treatment (Anglin and Hser, 1990; Leshner, 1999; 
Yahyavi-Firouz-Abadi and See, 2009). Relapse prevention strategies may be achieved using 
traditional psychotherapy and counselling and may also, like detoxification, be achieved 
using pharmacotherapies (Anglin and Hser, 1990; Yahyavi-Firouz-Abadi and See, 2009).  
Relapse prevention strategies aim to identify the psychological and environmental factors that 
may lead to drug cravings and relapse in patients, and equip patients with the skills to 
recognise and cope with these situations in a way that will minimize the chances of relapse 
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occurring (Anglin and Hser, 1990; Carey, 1990; Leshner, 1999). Relapse prevention 
programs also aim to educate patients that recovery is a long-term process and periodic 
relapses are to be expected. Relapses should not to be viewed as a failure, but strategies 
should be offered instead for coping with relapse if it does occur (Carey, 1990; Leshner, 
1999; O’ Brien, 2003).  
1.1.6.2 Pharmacotherapy  
The pharmacological treatment of drug addiction targets four main areas of patient 
management, namely; the pharmacological management of withdrawal symptoms, harm 
reduction, relapse prevention and pharmacological treatment to prevent or treat medical 
complications from substance abuse (Anglin and Hser, 1990; Lingford-Hughes et al., 2004; 
Watson and Lingford-Hughes, 2007).  
The management of withdrawal symptoms and harm reduction strategies may broadly be 
described as detoxification, which aims to reduce the quantity and frequency of substance use 
and consequently reducing the physical and psychological harms associated with its use 
(Carey, 1996; Lingford-Hughes et al., 2004).  
Detoxification may be achieved using agonist or partial agonist drugs, which act as short-
term licit drug substitutes when administered at a controlled dose (Anglin and Hser, 1990; 
Siegel and Ramos, 2002; Watson and Lingford-Hughes, 2007). During the process of 
detoxification, it is important that adequate care be given to the patient, not just for the 
medical symptoms of withdrawal, but also psychological symptoms which may result from 
drug misuse such as depression or anxiety (Anglin and Hser, 1990; Lingford-Hughes et al.,  
2004).  
Pharmacological intervention that maintain abstinence and prevent relapse typically consist 
of drugs which reduce the cravings for illicit substances or dampen withdrawal symptoms, 
which may persist long after detoxification (Siegel and Ramos, 2002; O’ Brien, 2003).   
Relapse prevention medications may include antipsychotics, antidepressants, anti-anxiety and 
even anti-obssessive drugs (O’ Brien, 2003). Although no medication offers a cure for 
addiction, in conjunction with psychotherapy they help to bring the patient back to being 




1.1.6.3 Drug types in addiction treatment  
The most well established agonist treatment used in both the short-term as part of 
detoxification, and the long-term as part of a maintenance regime, is the µ-opioid agonist 
methadone (McLellan et al., 2000; Lingford-Hughes et al.,  2004; Vocci et al., 2005; 
Yahyavi-Firouz-Abadi and See, 2009). Methadone, when administered orally, activates the 
same receptors as heroin and other opioid drugs, however it has a much lower abuse potential 
than these illicit opioid drugs. Methadone therefore acts as a licit substitute (Anglin and Hser, 
1990; O’ Brien, 2003; Watson and Lingford-Hughes, 2007).  
The abuse potential of a drug is dependent on its pharmacology, with drugs that illicit rapid 
onset of euphoria and having a shorter duration of activity having a higher abuse potential 
than those with a slower onset and a greater period of activity (O’ Brien, 2003).  These 
characteristics are a key component in substitution treatment, by utilising drugs that do not 
produce the alternating “highs” and “lows” that occur with drugs whose effects have a rapid 
onset but wane just as rapidly, ultimately create an urgent desire for another dose (O’ Brien, 
2003; Watson and Lingford-Hughes, 2007).  
Methadone’s effects have a delayed onset as well as long-lasting activity. It has a half-life of 
± 24 hours, which decreases its abuse potential in relation to that of heroin (McLellan et al., 
2000; O’ Brien, 2003; Watson and Lingford-Hughes, 2007). Methadone treatment has proven 
to be effective in reducing opiate use in addicts, with doses ranging from 80-120mg/day 
inhibiting the intravenous self-administration of heroin and hydromorphane (Leshner, 1999; 
McLellan et al., 2000; Vocci et al., 2005).  
Substitution treatments have also been used in the treatment of nicotine addiction, with 
nicotine replacement therapy (NRT) being shown to reduce cravings and withdrawal 
symptoms in addicts (Watson and Lingford-Hughes, 2007). NRT typically consists of 
patches,  gum and other preparations containing doses of nicotine that activate the nicotinic 
acetylcholine receptors, and replace some of what the smoker was getting from their 
cigarettes (Leshner, 1999; Watson and Lingford-Hughes, 2007).   
Although no medications have been approved for the treatment of psychostimulant abuse, 
clinical trials using Baclofen, a drug which has agonist effects on γ-aminobutyric acid B 
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(GABAB) receptors, have been shown to be effective in reducing cocaine self-administration, 
cravings, as well as the relapse rate in non-opioid dependent, non-treatment seeking cocaine 
addicts (Vocci et al., 2005; Yahyavi-Firouz-Abadi and See, 2009). However, there are 
conflicting results about Baclofen’s efficacy with heavily dependent cocaine users, with some 
studies indicating that the higher the level of abuse in patients at the baseline, the more they 
benefitted from treatment, and others indicating that Baclofen was not effective in initiating 
abstinence in heavy cocaine dependent patients (Vocci et al., 2005; Yahyavi-Firouz-Abadi 
and See, 2009). 
A new stimulant drug, which has been used to increase alertness in narcoleptic patients but 
also has been shown to be effective in the treatment of psychostimulant addiction, is 
Modafinil (Vocci et al., 2005). This drug, which exerts a stimulatory action via non-
dopaminergic pathways, enhancing glutamate activity in the brain, has a low abuse potential 
and has been associated with less craving for amphetamines, as well as less cravings and use 
of cocaine (Vocci et al., 2005; Yahyavi-Firouz-Abadi and See, 2009). Modafinil works in 
three ways in attenuating cocaine use; by decreasing symptoms of cocaine withdrawal, by 
blunting craving as well as subjective response to cocaine, thereby preventing cocaine 
priming and multiple-use episodes, and lastly, acts to decrease impulsive responding which 
allows time for cognitive systems and decision making skills to be utilized before drug use 
occurs (Vocci et al., 2005).  
The use of partial agonists in detoxification and maintenance programs is also common, with 
the dual agonist and antagonist properties of some of these drugs proving to be an effective 
treatment (Watson and Lingford-Hughes, 2007). The partial µ-opioid agonist buprenorphine 
has been used as an effective substitute for illicit opiate use, as it is able to occupy opioid 
rceptors but produce only a partial response (Watson and Lingford-Hughes, 2007). Therefore 
it activates the same receptors as illicit opiates but produces less euphoria, sedation and 
positive reinforcement than these opiates or indeed full agonist treatments (Watson and 
Lingford-Hughes, 2007). Buprenorphine also exerts antagonistic effects on κ-opioid 
receptors, the activation of which leads to dysphoria, sedation and depersonalization. Acting 
on these receptors buprenorphine produces less dysphoria in comparison to full agonist drugs 
(Watson and Lingford-Hughes, 2007). Buprenorphine is often used as an alternate substitute 
to methadone in both the detoxification and maintenance treatment programs (McLellan et 
al., 2000; Watson and Lingford-Hughes, 2007; Yahyavi-Firouz-Abadi and See, 2009).  
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The antidepressant drug bupropion has proven effective in the treatment of nicotine 
addiction, producing increased dopamine and norepinephrine levels in the mesolimbic system 
by acting as an uptake inhibitor (Lingford-Hughes and Nutt, 2003). This increase in 
dopamine levels is sufficient to reduce cravings and aid in the successful cessation of 
smoking in addicts (Gonzales et al., 2006; Watson and Lingford-Hughes, 2007). In addition 
to its effects on the mesolimbic dopamine pathway, bupropion has been shown to be a 
nicotinic antagonist; selectively blocking activation of neuronal acetylcholine nicotinic 
receptors (Slemmer et al., 2000). This blockade of the effects of nicotine via receptor 
antagonism, in addition to its dopamine release, suggests bupropion is a partial agonist at 
nicotinic acetylcholine receptors and this may explain its efficacy in the treatment of nicotine 
dependence (Slemmer et al., 2000). Due to the prominent role of dopamine in the addictive 
process, it has been a target of pharmacotherapy, where dopamine ‘stabilizers’ being either 
partial agonists or mixed action antagonists are used (Vocci et al., 2005). For example, a 
partial D3 agonist (BP – 897) has been developed as a possible strategy to block the binding 
of cocaine to its dopamine binding site (Lingford-Hughes and Nutt, 2003). This partial 
agonist has been shown to inhibit cocaine seeking behaviour in rodents in response to drug-
paired cues. It is thought to do so by stimulating the D3 receptor enough to prevent 
withdrawal symptoms without causing rewarding effects (Lingford-Hughes and Nutt, 2003). 
 Naltrexone is an orally administered opioid antagonist which has been shown to be effective 
as a maintenance treatment, as well as being effective as part of relapse prevention treatment 
in conjunction with psychosocial interventions (McLellan et al., 2000; Watson and Lingford-
Hughes, 2007). Naltrexone has a long lasting activity, with an effective half-life of 96 hours 
owing to its active metabolite, therefore resulting in long lasting blockade of the effects of 
heroin and other opiates by preventing them from binding to the µ-opioid receptor (Leshner, 
1999; Watson and Lingford-Hughes, 2007; Yahyavi-Firouz-Abadi and See, 2009).  
Naltrexone has also been effective in the treatment of alcohol dependence, with a dose of 
50mg/day resulting in less craving for alcohol, a reduction in drinking behaviours and a lower 
rate of relapse in alcohol dependent patients (Leshner, 1999; McLellan et al., 2000; O’ Brien, 
2003; Adinoff, 2007). Patients also reported less pleasure being felt when they eventually did 
have a drink (O’ Brien, 2003). This may be explained by the mechanism by which alcohol 
exerts its effects on the opioid system. In both human and animals, alcohol causes the 
activation of µ-opioid receptors, resulting in the stimulation of endogenous opioids, which 
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consequently activate the dopamine reward pathway (O’ Brien, 2003). Naltrexone has been 
shown to block the µ-opioid receptors that suppress GABA neurons, and therefore these 
neurons are able to inhibit ventral tegmental area dopamine neurons (Adinoff, 2007). This 
may explain the blockade of some of the “highs” associated with alcohol abuse and the lack 
of euphoria experienced by the alcohol dependent patients (McLellan et al., 2000; O’ Brien, 
2003).  
Naltrexone has also been used in cocaine addiction, where its interaction with relapse-
prevention psychotherapy has proven effective in decreasing the prevalence of relapse in 
abstinent, formerly dependent cocaine-addicted patients (Vocci et al., 2005). Interestingly, 
this effect was not seen when the drug was paired with any other behavioural therapy type 
(Vocci et al., 2005). 
Disulfiram is another drug which has been reported to have an enhanced effect in conjunction 
with specific types of psychotherapy (Vocci et al., 2005). An inhibitor of the sulfhydryl-
containing enzyme aldehyde dehydrogenase, which plays a key role in the metabolism of 
alcohol, disulfiram administration results in an accumulation of acetaldehyde after drinking 
alcohol (Watson and Lingford-Hughes, 2007; Vocci et al., 2005). This accumulated 
acetaldehyde causes unpleasant feelings such as nausea, vomiting, headache, flushing, 
palpitations and hypotension, and with a high enough consumption of alcohol may lead to 
unconsciousness and even death (Watson and Lingford-Hughes, 2007).  
The efficacy of this drug in decreasing alcohol intake is therefore due to the patient’s fear of 
these adverse reactions (Watson and Lingford-Hughes, 2007). Consequently, disulfiram has 
been marketed as a treatment for alcohol addiction, but has also been reported to decrease 
cocaine use (Watson and Lingford-Hughes, 2007; Vocci et al., 2005; Yahyavi-Firouz-Abadi 
and See, 2009). This decrease in cocaine use is due to disulfiram’s role as a dopamine 
metabolism inhibitor, and was observed particularly when disulfiram was paired with 
cognitive behaviour therapy. However this effect was less prevalent when disulfiram 
treatment was paired with interpersonal behaviour therapy (Vocci et al., 2005; Yahyavi-
Firouz-Abadi and See, 2009). 
The drug topiramate is also effective in the treatment of both alcohol and cocaine addiction, 
although marketed as an antiepileptic drug. Topiramate has both GABA enhancing and 
glutamate inhibiting properties (Vocci et al., 2005; Adinoff, 2007). Topiramate facilitates 
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GABA functioning through a non-benzodiazapine site on the GABAA receptor and 
antagonizes glutamate at AMPA and kianate receptors (Adinoff, 2007). Patients who were 
abstinent during a two week baseline period and were treated with a 200mg/day dose of 
topiramate showed a decrease in return to cocaine use as well as an increase in negative urine 
tests as compared to the placebo paired patients (Vocci et al., 2005; Yahyavi-Firouz-Abadi 
and See, 2009). 
A naturally occurring compound called Ibogaine has been shown to be an effective treatment 
in drug addiction, and has been shown to decrease the self-administration of cocaine, ethanol, 
morphine and nicotine in rodents (Adinoff, 2007). This indole alkaloid binds to κ-opioid, N-
methyl-D-aspartate (NMDA) glutamate and nicotinic receptors and has been shown to block 
the release of dopamine in the nucleus accumbens in cocaine sensitive animals (Adinoff, 
2007).  
Numerous other pharmacotherapeutic treatments exist, acting on various receptors and 
pathways within the brain to decrease the physical withdrawal symptoms and reduce cravings 
in addicts. However, just as vital in the treatment of addiction is the management of 
psychological harms that may be associated with drug misuse (Lingford-Hughes et al., 2004).  
 Symptoms of psychiatric disorders such as depression, anxiety and psychosis often present in 
patients who abuse drugs, and the presence of such symptoms may increase subsequent drug 
use, making treatment especially challenging (Lingford-Hughes et al., 2004). It is therefore 
vital that for effective harm reduction and relapse prevention, both the addiction as well as 
the psychiatric disorder be treated concurrently (Lingford-Hughes et al., 2004).  
Pharmacotherapy therefore plays a vital role in the treatment of addiction and in conjunction 
with behavioural therapies and support services, such as vocational rehabilitation and mutual 
support organizations such as Alcoholics and Narcotics Anonymous, can facilitate the return 
of drug and alcohol dependent patients to productive functioning (Anglin and Hser, 1990; 
Carey, 1996; Leshner, 1999).  
1.1.7 Animal Models of Addiction  
The definition of an animal model is an experimental preparation developed for the purpose 
of studying a condition found in humans. Animal models operate under the assumption that 
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homology or analogy can be found in the physiology and behaviours of various animal 
species and human beings (Markou et al, 1993). 
Animal models need to meet certain criteria in order to establish itself as a valid 
representation of the human condition it is proposed to model (Bakshi and Kalin, 2002). 
Three types of validity are generally used as a measure of the value of an animal model; face 
validity, construct validity and predictive validity (Bakshi and Kalin, 2002; Epstein et al, 
2006).  
Face validity refers to the similarity in appearance between the animal model and the human 
condition it is trying to represent; construct validity refers to the similarity in the internal 
mechanism underlying the behaviour or condition that is being modelled; and predictive 
validity refers to the extent to which the effects induced by an experimental protocol on an 
animal predicts the effects seen in humans when induced by a similar event (Markou et al, 
1993; Bakshi and Kalin, 2002; Epstein et al, 2006).  
Though it would be ideal for a model to meet all three of these criteria, it appears that in order 
for a model to establish itself as being valuable, it need only to meet the requirements of 
predictive validity and reliability (Markou et al, 1993; Koob, 2000).  
The reliability of a model depends upon the consistency and stability of the specific variables 
that are being observed (Markou et al, 1993; Geyer and Markou, 2000; Hitzemann, 2000). A 
model should be reproducible under similar conditions, and the effects they produce should 
be reproducible if the same manipulation is being applied, with minimal variability within 
individual subjects and between subjects (Markou et al, 1993; Geyer and Markou, 2000; 
Hitzemann, 2000).  
Various animal models exist to mirror the characteristics of drug addiction in humans, and 
while none seem to cover every aspect of addiction, they provide a valuable tool in the study 
of this mental disorder. 
Self-administration models of addiction study the acute rewarding properties of drugs of 
abuse, the development of habitual drug seeking and the ultimate development of addictive 
behaviour (Kalivas et al., 2006). In this model experimental animals will readily self-
administer drugs when given free access to it or after being trained to perform a task to gain 
the drug (Roberts and Koob, 1997; Shippenberg and Koob, 2002; Feltenstein and See, 2008). 
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Self-administration may be orally (mostly in the case of alcohol), intracranial or 
intravenously via a chronic indwelling catheter, and generally drugs with a higher abuse 
potential elicit greater self-administration in the animals (Figure 2, Koob, 2000; Shippenberg 
and Koob, 2002; Feltenstein and See, 2008). This animal model has been widely used 
because it has both reliability and good predictive validity (Shippenberg and Koob, 2002).  
Intracranial self-stimulation (ICSS) involves the implantation of intracranial electrodes into 
brain areas involved in motivation and reward, where animals will be able to press a lever in 
order to receive a short, mild train of electrical stimulation (Figure 2, Roberts and Koob, 
1997; Shippenberg and Koob, 2002; Feltenstein and See, 2008). Animals will self-administer 
this current at high frequency to the areas of the brain that bring about reward, showing that 
stimulation of such areas is reinforcing (Roberts and Koob, 1997). The administration of 
drugs of abuse have been shown to decrease the amount of current required to achieve the 
same level of reward (Shippenberg and Koob, 2002; Feltenstein and See, 2008).  Therefore, it 
can be shown that the greater the abuse potential of the drug, the greater its ability to decrease 
the ICSS threshold resulting in requiring less stimulation to achieve the same level of reward 
(Roberts and Koob, 1997; Shippenberg and Koob, 2002; Feltenstein and See, 2008). ICSS is 
commonly used as it has been shown to have excellent predictive validity for the abuse 
potential of drugs (Koob, 2000).  
Conditioned place preference (CPP) paradigms use the principles of classical conditioning to 
model addiction in animals (Koob, 2000; Feltenstein and See, 2008). CPP uses the natural 
reward system of the nucleus accumbens as well as the learning and memory circuit within 
the dorsal hippocampus to allow for a learnt association to occur between the euphoric effects 
of the drug of abuse and a particular environment, through repeated pairings of the two 
(Tropea et al., 2008) The animal is exposed to an apparatus comprised of two initially neutral 
environments differing either in colour, texture, odour or lighting (Feltenstein and See, 2008). 
The animal is exposed to a drug in one of the compartments and to a vehicle in the other, 
thereby conditioning it to associate that particular environment with the drug (Roberts and 
Koob, 1997; Feltenstein and See, 2008). After a number of treatment sessions the animal is 
given free access to the entire apparatus and its preference is assessed. According to the 
principles of classical conditioning, if the drug has reinforcing properties the animal should 
spend a greater amount of time in the drug-paired compartment, indicating seeking behaviour 
(Figure 2, Roberts and Koob, 1997; Shippenberg and Koob, 2002; Feltenstein and See, 2008).  
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The CPP paradigm demonstrates both reliability and validity, with drugs producing 
conditioned preferences for the drug-paired environment also functioning as positive 
reinforcers within other addiction paradigms (Shippenberg and Koob, 2002). CPP, like ICSS 
and self-administration models, also provides predictive validity for the abuse potential of 
drugs (Koob, 2000). CPP has been proven useful as an inexpensive means to assess the 
rewarding properties of a substance quickly and with minimal training required. Various 
drugs of abuse, such as opiates, cocaine and nicotine, have been shown to produce CPP, 
sometimes using a single drug pairing at relatively low doses (Feltenstein and See, 2008).  
The reinstatement model of CPP has also demonstrated reliability and predictive validity, 
with reinstatement in laboratory animals being induced by conditions that have been reported 
to trigger drug craving and relapse in human addicts, such as acute re-exposure to the drug, 
drug related cues or stress (Epstein et al, 2006). The reinstatement of extinguished drug-
seeking behaviours in response to the priming drug dose or drug associated cues occur in 
predictable ways and further demonstrates the predictive validity of this model (Shippenberg 
and Koob, 2002).   
However, the use of the CPP model has been shown to have disadvantages and may display a 
measure of unreliability as compared to self-administration models. CPP models rely on the 
non-contingent administration of the drug, and animals never experience contingent drug 
administration, which is the hallmark of addiction (Shippenberg and Koob, 2002; Feltenstein 
and See, 2008). The neurochemical and behavioural effects of a drug have been shown to be 
directly influenced by whether the administration of the drug is being controlled by the 
subject, so a passive exposure to the drug may not always result in the development or 
appearance of seeking behaviour (Shippenberg and Koob, 2002).  
In order to obtain reliable data, factors such as method of administration (i.p or s.c), number 
of environmental pairings and duration of pairings must be carefully controlled, as they can 
profoundly affect conditioning behaviour (Shippenberg and Koob, 2002; Feltenstein and See, 
2008). The number and duration of the pairings is vital in order to avoid the issue of 
familiarity and preference bias, which can result in inaccurate behavioural results on the test 
day (Koob, 2000; Feltenstein and See, 2008). Genotypic differences need also be taken into 
account, in terms of sensitivity to drugs, as well as the saliency of environmental cues. These 
differences may result in a decrease in the reinforcing effects of the drug or a failure to 
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establish the learning and memory processes involved in associative conditioning 













In summary, addiction presents as a chronically relapsing disorder involving compulsive 
taking of drugs, and the development of withdrawal symptoms upon its cessation. Many 
theories have been proposed to explain the mechanism by which addiction is established, 
with some theories focusing on dysfunctions in learning and memory pathways. Within these 
learning and memory models, LTP and LTD have been postulated as a possible mechanism 
by which addiction can develop. At present, treatment options for addicts consists of 
psychotherapy and pharmacotherapy, and are dependent on the underlying cause of the 
addictive behaviour. However, due to the high occurance of relapse in addicts, much interest 
has been given to the study of addiction and its treatment. To that end numerous animal 
models of addiction have been developed to mirror the addictive state in order to research its 
pathophysiology and possible treatments. 
Figure 2: Animal models of drug addiction. A – Self administration     
B – Intracranial self stimulation C – Conditioned place preference 




1.2.1 Dopamine synthesis 
Dopamine is the catecholaminergic neurotransmitter that is primarily associated with the 
addictive state. It acts within the central nervous system to control a variety of functions via 
three neural pathways namely the nigrostriatal, tuberoinfundibular and mesolimbic pathways 
(Pivonello et al., 2007). It is synthesized from the amino acid tyrosine (found in abundance in 
dietary proteins) which is then converted to L-dopa by the enzyme tyrosine hydroxylase 
(TH). L-dopa is then converted to dopamine via the enzyme aromatic amino acid 
decarboxylase (AADC). The resultant dopamine is then sequestered into storage vesicles by 








Figure 3: Dopamine synthesis and storage pathway 
(Adapted from Lawlor et al., 2004) 
1.2.2 Dopaminergic receptors 
1.2.2.1 Dopamine receptor structure 
Dopamine released into the synaptic cleft binds to dopaminergic receptors of which there are 
at least 5 different types, namely D1, D2, D3, D4 and D5. These receptors share structural 
characteristics in that they are all G-protein coupled receptors. As such they consist of seven 
putative membrane spanning helices which form a narrow dihedral hydrophobic cleft, 
23 
 
surrounded by three extracellular and three intracellular loops (Figure 4, Civelli, 2000; 












Figure 4: Dopamine receptor structure.  
Structural features of D1-like receptors are represented. D2-like receptors are characterized by a 
shorter COOH-terminal tail and by a bigger third intracellular loop. Residues involved in ligand 
binding are highlighted in transmembrane domains. Potential phosphorylation sites are represented on 
the third intracellular loop (I3) and on the COOH terminus. The potential glycosylation sites are 
represented on the NH2-terminal. E1–E3, extracellular loops; 1–7, transmembrane domains; I2–I3, 
intracellular loops.    
(Pivonello et al., 2007) 
1.2.2.2  The Dopamine receptor family 
Dopamine and other monoamines do not ‘mediate’ fast synaptic transmission in the central 
nervous system, but rather modulate it (Iverson et al., 2007) This dopamine-dependent signal 
transduction is activated through the interactions with membrane receptors belonging to the 
7-trans membrane domain G-protein coupled receptors, of which there are five different 
types, namely D1, D2, D3, D4 and D5 dopaminergic receptors (Samad et al., 1997; Civelli, 
2000; Iverson et al., 2007; Janhunen et al., 2007; Pivonello et al., 2007).  
Functionally there are two broad groups of dopamine receptors within the dopamine receptor 
family which are derived from the divergence of two gene families, namely the D1 – like 
receptors (D1 and D5), which are associated with stimulatory functions, and D2 – like 
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receptors which are associated with inhibitory functions (Civelli, 2000; Pivonello et al., 
2007). All the members of the dopamine receptor family are encoded by genes which are 
localized at different chromosomal loci, yet they display considerable homology in their 
protein structure and function (Pivonello et al., 2007). D1- like receptors are encoded by 
genes that lack introns in their proton coding regions and in their transmembrane domains, 
whereas D2, D3 and D4 genes do possess the introns (Civelli, 2000). D1 and D5 share a 79-
80% homology and are only 40-45% identical to the D2-like receptors (Civelli, 2000; 
Pivonello, 2007). D2 receptors share a 75% homology with D3 receptors and are between 51-
53% identical to the D4 transmembrane domains. All three of the D2-like receptors are being 
encoded by genes that are interrupted by introns, with these introns being found in similar 
positions (Civelli, 2000; Pivonello, 2007). D1-like and D2-like receptors differ in their 
transmembrane domains by 21 amino acid residues and apparently this feature facilitates 
selective recognition processes by the two types of receptors (Civelli, 2000).  
The dopamine receptors display some heterogeneity in their expression and distribution in 
various cells, tissues and organs and in this way it is able to stimulate and/or inhibit different 
functions (Iverson et al., 2007; Pivonello et al., 2007). For instance, the limbic system 
predominantly shows selectivity of D2-like receptors, with hardly any sign of D1-like 
receptors. These receptors are located both pre and post synaptically (Iverson et al., 2007; 
Pivonello et al., 2007), indicative of its role in controlling neurotransmission of especially 
dopamine (Samad et al., 1997).   
1.2.2.3 Mechanism of action   
D1-like and D2-like receptors exert their actions and modulate the effects of dopamine and 
dopaminergic compounds by coupling to and activating different G-protein complexes. Their 
primary biological activities are the activation and inhibition of adenylyl cyclase respectively, 
resulting in the stimulation or inhibition of cAMP accumulation (Civelli, 2000; Pivonello et 
al., 2007). The result of stimulation or inhibition of cAMP is the modulation, either activation 
or inactivation of protein kinase A, which through either phosphorylation or 
dephosphorylation regulates the synthesis of various cytoplasmic and nuclear proteins, the 
functioning of membrane channels, and the sensitization or desensitization of other G-protein 
couple receptors (Pivonello et al., 2007). 
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Stimulation of D1 and D5 receptors causes interactions with the Gs or Gi stimulating complex 
to activate adenylyl cyclase and stimulate cAMP accumulation, indicating similar pathways 
of second-messenger induction for D1-like receptors (Figure 4, Civelli, 2000; Iverson et al., 
2007). Dopamine D1-like receptors have a short third intracellular loop, which is typical for 
receptors that interact with Gs proteins to stimulate cyclic AMP production (Pivonello et al., 
2007). Dopamine acting on D1 receptors activates the formation of cyclic AMP, which 
activates a cAMP-sensitive protein kinase that causes an increase in the phosphorylation of a 
substrate known as DARPP-32 (Dopamine and cAMP regulated phosphoprotein, molecular 
weight 32kDa) and simultaneously inhibiting phosphatase 1 (Figure 5, Iverson et al., 2007). 
DARPP-32 has a key role in mediating the actions of dopamine by linking these to numerous 
other neurotransmitter mechanisms, ion channels and transcription factors (Iverson et al., 
2007).  
Activation of dopamine receptors may also lead to the stimulation of other signal 
transduction pathways, which include modulating the activity of phospholipase C or releasing 
arachidonic acid, calcium and potassium channels, as well as sodium/hydrogen exchange and 














Figure 5: D1-like receptor signaling pathways.  
Stimulatory effects are indicated with a solid line ending in an arrowhead, and inhibitory 
effects with a dashed line ending in a bar. AC5, adenylate cyclase type 5; CREB, cyclic AMP 
response element binding protein; DARPP-32, dopamine-related phosphoprotein, 32 kDa; 
MAPK, mitogen-activated protein kinase; NHE, Naþ/Hþ exchanger; PKA, protein kinase A; 
PKC, protein kinase C; PLC, phospholipase C; PP1 or PP2A, protein phosphatase 1 or 2A. 




D2-like receptors, on the other hand, have long third intracellular loops, which are 
characteristic for receptors which interact with G inhibitory or Gi proteins to inhibit the 
production of cyclic AMP (Civelli, 2000; Pivonello, 2007). It therefore seems as if it is the 
third intracellular loop that is responsible for selective control of G-protein coupling and 
signal transduction (Pivonello et al., 2007). The D2 famly of receptors are further divided 
into D2S and D2L receptors. The D2S receptor specifically, when activated, induces the 
stimulation of phospholipase D, which is the enzyme that catalyses the hydrolysis of 
phosphatidylcholine to phosphatidic acid and choline. (Figure 6, Pivonello et al., 2007). The 
resultant acid, together with diacylglycerol, are signalling molecules that have been 
implicated in a number of pathways that regulate cell metabolism, cell growth and 
differentiation (Pivonello et al., 2007). Dopamine receptors control growth and 
differentiation via activating mitogen-activated protein kinase (MAPK) and the extracellular 
signal-regulated kinase (ERK) pathways (through the involvement of Gβγ subunits and 
protein kinase C). These pathways have also been implicated in the regulation of apoptosis 
(Pivonello et al., 2007).  
The D4 receptor isoform differs from other dopamine receptors in terms of the length of its 
third cytoplasmic loop, and also due to the presence of the same insert of a stretch of 16 
amino acid residues that occurs one, four, seven or eleven times in their protein structure 

















Figure 6: D2-like receptor signaling pathways. 
Stimulatory effects are indicated with a solid line ending in an arrowhead, and inhibitory 
effects with a dashed line ending with a bar. AA, arachidonic acid; AC2 or AC5, adenylate 
cyclase type 2 or 5; CREB, cyclic AMP response element-binding protein; DARPP-32, 
dopamine- and cyclic AMP-regulated phosphoprotein, 32 kDa; MAPK, mitogen-activated 
protein kinase; NHE, Naþ/Hþ exchanger; PA, phosphatidic acid; PC, phosphatidylcholine; 
PI3K, phosphatidylinositol 3-kinase; PKA, protein kinase A; PKC, protein kinase C; PLA2, 
phospholipase A2; PLC, phospholipase C; PLD, phospholipase D; PP1 or PP2A, protein 
phosphatase 1 or 2A; RTK, receptor tyrosine kinase. 
(Adapted from Neve et al., 2004) 
 
1.2.2.4 Distribution of dopamine receptors 
Dopamine is widely distributed throughout the central nervous system, in particular the 
dopaminergic neurons in the substantia nigra, ventral tegmental area and hypothalamus that  
give rise to the three main dopamine pathways, the nigrostriatal, the mesolimbic and the 


















Figure 7: Illustration of the three dopaminergic pathways in the brain 
(cnsforum.com) 
Dopamine receptors are therefore mainly localized within these pathways, in the striatum, the 
limbic system, the brain cortex and the infundibulum (Figure 9, Samad et al., 1997; Pivonello 
et al., 2007). In the mesolimbic and nigrostriatal pathways, both D1 and D2 receptors are 
present (Civelli, 2000). Specifically, there are high levels of D1 and D2 mRNAs expressed in 
the caudate putamen (CPu), nucleus accumbens and olfactory tubercle, with lower levels seen 
in the septum, hypothalamus and cortex (Civelli, 2000). Within the substantia nigra, 
hippocampus and the ventral tegmental area, there is high expression of D2 but not D1 
mRNA, whereas in the amygdala there is expression of D1 receptors but little, if any D2 
mRNA (Civelli, 2000). The expression of high levels of D2 dopamine receptors in the 
pituitary gland mediates the effect of dopamine in the regulation of prolactin gene expression 
and secretion (Figure 8; Samad et al., 1997; Civelli, 2000; Cheung and Lustig, 2007; 
Pivonello et al., 2007; Fitzgerald and Dinan, 2008). Dopamine acts via D2 receptors present 
on the cell membranes of lactotrophs, the activation of which results in the suppression of 
prolactin gene expression and the inhibition of prolactin exocytosis (Cheung and Lustig, 
2007; Fitzgerald and Dinan, 2008). Gene expression of prolactin is suppressed by the 
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inhibition of adenylyl cyclase and inositol phosphate metabolism, and exocytosis is inhibited 
due to modification of potassium and calcium channels (Cheung and Lustig, 2007; Fitzgerald 








Figure 8: Short-loop feedback mechanism of prolactin regulation. 
DA, dopamine; TIDA, tuberoinfundibular dopaminergic neuron; Prl-R, prolactin receptor; 
D2R, dopamine2 receptor; PRL, prolactin. 
(Adapted from Fitzgerald and Dinan, 2008) 
The D3-D5 receptors are mostly present where D1 and D2 mRNA is expressed, but their 
abundance is lower than the D1 or D2 mRNA (Civelli, 2000). Relative to D1 and D2, the D3 
and D4 receptor subtypes are more selectively associated with the limbic brain areas and 
relatively absent in the nigrostriatal system. The limbic system mostly receives inputs from 
the ventral tegmental area to influence cognitive, emotional and endocrine functions of the 
brain and as such, is associated preferentially with the etiology of psychoses rather than 
locomotor dysfunctions (Civelli, 2000). D5 receptors in the central nervous system are highly 
specific, only being found in the hippocampus, the hypothalamus and the parafascicular 
nucleus of the thalamus (Figure 9). Here the receptors are said to be involved in affective, 





Figure 9: Distribution of dopamine receptors in the brain 
(CNSforum.com) 
Dopamine receptors are also found widely distributed in the periphery, mainly in the 
cardiovascular system, the kidneys and the adrenal glands (Pivonello et al., 2007). In the 
kidney and heart, D1- and D2-like activities have been described with D4 receptors being 
seen in the heart and low levels of D5 activity in the kidneys. In the heart dopamine may 
increase cardiac output, while in the kidney it seems to stimulate the renin-angiotensin 
system. The presence of dopamine in the adrenal glands suggests a role for these receptors in 
the regulation of adrenal hormone synthesis or secretion (Pivonello et al., 2007). 
 
1.2.3 Dopamine pathways 
The dopaminergic system plays a pivotal role in the central nervous system and also plays a 
smaller part in the periphery, particularly in the endocrine, cardiovascular, renal and 
gastrointestinal systems (Samad et al 1997; Civelli, 2000; Pivonello et al., 2007). Within the 
brain, the transmission of dopamine is responsible for the control of various physiological 
functions, including cognition, emotions, hunger, satiety, coordination of movement and the 
synthesis and secretion of hormones, as well as the regulation of the hypothalamo-pituitary-




There are three dopaminergic pathways within the central nervous system, namely; the 
nigrostriatal pathway, the tubero-infundibular pathway, and the mesocorticolimbic pathway 
(Figure 7, Behrouz et al 2007; Janhunen et al., 2007).  
 
The nigrostriatal dopamine pathway consists of the axons of neurons whose cell bodies are 
located in the substantia nigra pars compacta. These neurons project mainly to the dorsal 
striatum, the CPu. This pathway is a key component of the extrapyramidal motor system and 
is involved in the control of posture and motor behaviour as well as the learning of motor 
programs and habits (Figure 7, Civelli, 2000; Behrouz et al., 2007; Janhunen et al., 2007). 
Degeneration of the nigrostriatal pathway underlies the development of extrapyramidal 
abnormalities that include Parkinson’s disease (Civelli 2000; Janhunen et al., 2007).  
The tubero-infundibular dopamine neurons form part of a heterogeneous group of dopamine 
neurons in the brain which originate in the arcuate nucleus of the mediobasal hypothalamus 
and project ventrally into the median eminence to terminate adjacent to the hypophyseal 
portal vessels (Figure 7, Behrouz et al., 2007). The dopamine that is released into the portal 
circulation is transported to the anterior pituitary where it tonically inhibits the secretion of 
prolactin (Behrouz et al., 2007). The re-uptake of dopamine is mediated by the action of high 
volume–low affinity dopamine transporters and low volume-high affinity dopamine 
transporters (Behrouz et al., 2007). Unlike other dopamine neurons, the neurons of the 
tubero-infundibular pathway are not affected in Parkinson’s disease (Behrouz et al., 2007). 
The mesolimbic dopamine projections  originate in the midbrain, specifically the ventral 
tegmental area and have three major trajectories namely the dorsal striatum, ventral striatum 
(including the nucleus accumbens) and the prefrontal cortex and other limbic structures 
(Figure 7, Civelli, 2000; Shephard et al., 2006; Behrouz et al., 2007; Iverson, 2007; Janhunen 
et al., 2007). These long midbrain dopaminergic projecting axons form classic synapses with 
their target neurons. Usually dopaminergic synaptic activity is regulated by a dopamine 
autoreceptor-mediated mechanism (Behrouz et al., 2007). Apart from projecting into the 
nucleus accumbens, the ventral tegmental area has dense connections that terminate in the 
medial pre-frontal cortex, temporal cortices, ventral pallidum and basal forebrain structures 
such as the amygdala, bed nucleus of the stria terminalis and the lateral septum (Dobbs et al., 
2008, Herrold et al., 2008).  
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The mesocorticolimbic pathway plays a critical role in diverse motivational processes 
including procuring and consuming food, engaging in sexual behaviour as well as in drug 
reward and addiction-like behaviour (Dobbs et al., 2008; Herrold et al., 2008). Each of the 
structures within this pathway carries out different yet important functions that cumulatively 
have been implicated in reward e.g. the ventral tegmental area, the nucleus accumbens and 
the ventral pallidum have all been shown to be critically involved in psychostimulant (such as 
methamphetamine) drug-induced behaviour in rats (Herrold et al., 2008). The cortical and 
limbic areas of the brain which receive projections from the ventral tegmental area are 
important for the expression of emotions, reactivity to conditioned cues, planning and 
judgement and have therefore been implicated in reward (Tomkins and Sellers, 2001).  
 
As well as having a well-established role in the development of drug dependence and reward 
behaviour, the mesocorticolimbic system is the principle dopaminergic pathway involved in 
the etiology of psychosis (Civelli, 2000; Janhunen et al., 2007). This leads to difficulties with 
regard to dopamine-related treatments as blockade of the dopamine system may reduce 
psychoses and drug dependence but lead to side–effects that include extrapyramidal 
dysfunctions (Civelli 2000).  
The terms mesolimbic and mesocortical systems are sometimes used instead of the combined 
mesocorticolimbic system due to the difference in their functional properties. (Janhunen et 
al., 2007). It is the mesolimbic pathway that is responsible for the control of motor behaviour 
and motivation, emotions and rewards whereas the mesocortical system is involved in higher 
cognitive functions such as working memory, as well as learning and reward (Janhunen et al., 
2007).  
1.2.4 Dopamine in motivation and reward 
Animals are able to learn goal-directed behaviour based on their knowledge of the potential 
outcome of their actions and the value of these outcomes, in a learning paradigm known as 
‘the cognitive value system’ (Iverson et al., 2007). There is also a second value system that 
operates when we experience reinforcement and when we determine how much we ‘like’ the 
outcomes of our actions or behaviours- in this case the term ‘pleasure’ is often used (Iverson 
et al., 2007).  
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Dopamine plays a significant role in this reward and reinforcement paradigm and is at the 
centre of a complex neural circuitry that each contributes to the component processes that 
make up reinforcement, motivation and learning (Iverson et al., 2007). The intimate relation 
of the nucleus accumbens to areas of the limbic system that are innervated by dopaminergic 
neurons has led to the proposal that the mesolimbic dopamine pathway is central to these 
behaviours.  
The nucleus accumbens can be divided into core and shell subregions and these regions differ 
in terms of neuronal organization and efferent targets, with the shell including projections 
from the substantia nigra (A9) mesencephalic neurons (Iverson et al., 2007). This pattern 
organization puts the nucleus accumbens shell in control of vast areas of the striatum and 
enables it to strengthen behaviours that are otherwise coordinated by the nucleus accumbens 
core and the dorsal striatum (Iverson et al., 2007). The core of the nucleus accumbens 
transmits information about the importance or the salience of the stimuli that we are exposed 
to on a daily basis, and this includes our sensitivity to rewarding or aversive stimuli, 
unexpected stimuli, condition reinforcers, as well as to their predictability or novelty (Iverson 
et al., 2007; Volkow et al., 2007; Dobbs et al., 2008).   
The nucleus accumbens core is particularly functional in the learning of an association 
between two stimuli or classical conditioning (referred to as S-S learning), unlike the dorsal 
striatum which is mostly involved in the learning of an association between a stimulus and a 
response (referred to as S-R learning) (Messinger et al., 2001; Iverson et al., 2007; Everitt et 
al., 2008). During S-S associative learning an initial neutral stimulus precedes a second 
stimulus, the latter of which elicits a particular response (Clark et al., 1998; Messinger et al., 
2001; Mok et al., 2010). Repeated exposure to these two stimuli results in long-term 
associative memories being formed. This is facilitated by the strengthening of the 
connections between the neurons representing the two stimuli (Messinger et al., 2001). The 
final outcome of this arrangement is that initally a neuron that would respond to only one of 
the associated stimuli will now respond to both (Clark et al., 1998; Messinger et al., 2001; 
Mok et al., 2010). This results in the original neutral stimulus now being able to elicit a 
response even in the absence of the second stimulus.  
Therefore individual neurons respond to sensory stimuli that become associated with a 
response or a reward (S-R associative learning) (Messinger et al., 2001; Mok et al., 2010). 
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The stimulus elicits a response and for every correct response given, a reward is received 
which strengthens the association between the stimulus and the action or response (Messinger 
et al., 2001; Mok et al., 2010). This type of associative learning allows the learning of an 
action through the consequences of response outcomes and reiterates that behaviours that are 
reinforced positively are more likely to reoccur (Mok et al., 2010).  
The dopamine inputs to both the nucleus accumbens and the striatum ensure a coordinated 
mechanism of modulation of goal-directed and procedural learning. This arrangement allows 
the balance between these two paradigms and facilitates adaptation to the environment as the 
animal experiences changes in stimuli and events (Iverson et al., 2007). 
This diversity of dopamine effects is likely translated by the specific brain regions it 
modulates, i.e. limbic, cortical and striatal (Volkow et al., 2007). 
Phasic fast-burst firings of dopamine neurons, (firing at a frequency of > 30Hz) which occur 
when there are large transient increases in the release of synaptic dopamine, are functionally 
relevant signals at post-synaptic sites that encode reward predictions or incentive salience. 
These signals also facilitate learning, and are involved in the reinforcing effects of drugs 
(Iverson et al., 2007; Volkow et al., 2007). This phasic burst firing contrasts to normal tonic 
dopamine cell firing which is slow at approximately 5Hz and is responsible for the 
maintenance of baseline, steady state dopamine. This slow firing is believed to set the overall 
responsiveness of the dopamine system.  
The mesolimbic dopamine system projects beyond the nucleus accumbens and the pathways 
that project to the amygdala are vital for the associative Pavlovian learning that underlies the 
responses of animals to salient or rewarding events (Iverson et al., 2007). Due to the 
important role of dopamine transmission in numerous behavioural responses, a disruption of 
these associative processes can lead to devastating effects, causing complex central nervous 
system disorders such as the inappropriate effects in schizophrenia, heightened distractibility 
in attention deficit hyperactivity disorder, as well as the development of drug addiction  
(Iverson et al., 2007; Janhunen et al., 2007).  
The reinforcing effects of drugs of abuse are not only dependent on increases in striatal 
dopamine but also on the rate of that increase, with a faster increase leading to more intense 
reinforcing effect (Volkow et al., 2007). An increase in the level of dopamine in the dorsal 
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striatum is involved in the motivation to procure a drug when the addicted subject is exposed 
to a stimulus which they associate with the drug (conditioned stimuli) (Volkow et al., 2007). 
Long-term use of drugs has been shown to decrease dopamine function with corresponding 
reductions in D2 receptor expression and dopamine release in the striatum in addicted 
subjects (Volkow et al., 2007). Reductions in D2 receptors in the striatum are associated with 
a reduction in the activity of the orbitofrontal cortex, which is the area of the brain 
responsible for salience attribution and motivation and with compulsive behaviours. Similarly  
reduced activity of the cingulated gyrus, the region that is involved in inhibitory control and 
impulsivity, is part of the repertoire of frontal regions of the brain implicated in the loss of 
control and compulsive drug intake by which addiction is characterized (Volkow et al., 
2007).  
1.2.5 Dopamine in methamphetamine addiction 
Brain imaging studies conducted on chronic methamphetamine abusers showed a decrease in 
dopamine transporter levels, an effect that can persist for months after cessation of drug use 
(Shephard et al., 2006). Chronic methamphetamine use also reduced the tissue levels of 
dopamine as evidenced by post-mortem studies (Shephard et al., 2006).  
Methamphetamine increases dopamine levels by releasing it from the terminals via the 
dopamine transporters (Volkow et al., 2007). Intravenous administration of 
methamphetamine increased extracellular dopamine concentrations in the striatum and this 
increase was associated with an increase in self-reports of highs and euphoria (Volkow et al., 
2007). The speed at which the drug enters the brain also affects their reinforcing effects and 
therefore intravenous administration enters the brain faster and induces faster dopamine 
changes when compared to oral administration, which results in a slow increase of dopamine 
levels (Volkow et al., 2007). Interestingly in methamphetamine use, it is the fast uptake of 
the drug that is associated with the development of the high, and not the actual brain 
concentration (Volkow et al., 2007).  
In summary, dopamine is a catecholaminergic neurotransmitter involved in numerous 
physiological functions, including the addictive state. Dopamine acts via three pathways in 
accordance with its function, namely the nigrostriatal, tuberoinfundibular and mesolimbic 
pathways. Within these pathways, dopamine exerts its effects via 5 different receptors, i.e. 
D1-D5, which exerts either a stimulatory or inhibitory effect. Within the mesolimbic system, 
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dopamine plays a role in reward and reinforcement, as well as the motivation and learning 
processes involved in addiction. These roles are mediated by the D1 and D2 receptors present 
in these neurocircuits. The administration of methamphetamine has been shown to increase 
dopamine transmission in this pathway, and this has been linked with the drugs reinforcing 























1.3.1 The methamphetamine problem 
Methamphetamine is a highly addictive stimulant drug whose illicit use and resultant 
addiction has become an alarming global phenomenon (Herrold et al., 2008). In 2000, the 
National Household Survey on Drug Abuse showed that approximately 8.8 million people 
have tried methamphetamine at least once. This potent central nervous system stimulant drug 
has become one of the world’s most widely abused illicit substances (National Institute of 
Drug Abuse, 2008). In South Africa, the abuse of this drug has increased dramatically with a 
report from the United Nations Office on Drugs and Crime (UNODC) on 23 July 2008 
stating that, “while dagga is the drug most abused in South Africa, amphetamine-style 
stimulants like tik (methamphetamine) pose the greatest threat on the drugs market.”  
1.3.2 Chemistry 
Methamphetamine is a chemical compound belonging to the amphetamine family and is the 
most widely abused of all amphetamine-like drugs (Albertson et al., 1999; Phillips et al., 
2008). All amphetamines share a common phenylethylamine skeleton, which can be altered 
at its α-ring, β-ring or its phenyl ring, in order to bring about various pharmacological actions 
(Figure 10, Albertson et al., 1999). Methamphetamine is distinctive from other amphetamines 
by the presence of two methyl groups located on the α-side chain and the amine group of this 
skeleton (Figure 11, Albertson et al., 1999). Therefore the systemic name for 
methamphetamine is N, α–dimethylphenethylamine with a chemical formula of C10H15N 
(Logan, 2002). Methamphetamine is the most hyperstimulating of the amphetamine 
analogues with the impact of its psychological and behavioural functions being due to its 
effects on the neurochemistry of the central nervous system (Halikitis et al., 2001). 
 





Figure 10: Basic Phenylethylamine structure Figure 11: Methamphetamine structure 




Methamphetamine exists in two isomeric forms with the two enantiomers being, 
dextrorotatory (D) methamphetamine (the more active enantiomer) and levorotatory (L) 
methamphetamine (the less active enantiomer) (Fowler et al., 2007; Mendleson et al., 2008). 
The configuration at the chiral centre dictates the central nervous system activity of the 
compound, with the d-isomer of methamphetamine having stimulant effects on the central 
nervous system up to 3-4 times greater than the L-isomer (Logan, 2002).  
The d-methamphetamine isomer differs from its L-isomer in both physiologic and 
pharmacologic potency, being more potent and having a more intense central 
psychostimulant effect (Shoblock et al., 2002; Fowler et al., 2008). For this reason D-
methamphetamine has a higher abuse liability than its L-isomer and is a prescription drug 
(DEA schedule II), while L-methamphetamine is an easily available over-the-counter drug 
(Fowler et al., 2007; Mendleson et al., 2008; Dufka et al., 2008). L-methamphetamine acts as 
a nasal decongestant and is the active ingredient in the Vicks
®
 Vapor Inhaler produced in 
America (Logan, 2002; Fowler et al., 2007; Mendleson et al., 2008; Dufka et al., 2008).   
1.3.3 Synthesis 
 D-methamphetamine is also relatively easy to synthesize and this leads to its illicit 
production in clandestine laboratories (Albertson et al., 1999; Barr et al., 2006; Fowler et al., 
2007). There are two common methods of illicit methamphetamine production, both by the 
reduction of ephedrine or its cousin pseudoephedrine (Figure 12, Derlet et al., 1990; Logan, 
2002, Fowler et al., 2007).  
The first method uses hydriodic acid and red phosphorus to bring about the reduction of L-
ephedrine or D-pseudoephedrine (Figure 12, Derlet et al., 1990; Logan, 2002, Fowler et al., 
2007). The resultant product with either precursor is pure D-methamphetamine, with yields of 
54-82% (Logan, 2002). Red phosphorus is easily obtained from the striker plates of 
matchboxes or road flares, while hydroiodic acid is relatively easy to synthesize from iodine 
(Logan, 2002).  
The second method of methamphetamine synthesis uses either sodium or lithium metal in 
condensed liquid ammonia to reduce either of the two precursor compounds (Figure 12, 
Logan, 2002). The lithium required for this method can be obtained from lithium batteries, 
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while the sodium is made from the electrolytic reduction of molten sodium hydroxide and 
liquid ammonia (Logan, 2002). The enantiospecific product from this method is also D-
methamphetamine (Logan, 2002).  
In either method of production, the substitution of phenylpropanolamine as the precursor will 
result in the synthesis of amphetamine (Logan, 2002). 
D-methamphetamine is a lipid soluble, pure base form of methamphetamine that is highly 
volatile and evaporates when exposed to air (Derlet et al., 1990). Therefore the form of 
methamphetamine that is commonly sold under the names “speed”, “tik” or “crank” is 
methamphetamine hydrochloride, which is D-methamphetamine which has been converted to 
a water-soluble crystalline form by using hydrochloride (Derlet et al., 1990).  
 
 
                  
Ephedrine      Methamphetamine 
 
(Adapted from www.chm.bris.ac.uk/motm/methamphetamine/methh.htm) 
1.3.4 Medical uses 
While D-methamphetamine is a potent addictive drug abused worldwide, it is noteworthy that 
it is currently marketed as Desoxyn® (Abbott Laboratories) for the treatment of Attention 
Deficit Disorder and Attention Deficit Hyperactivity Disorder (an alternative to the more 
commonly used methylphenidate (Ritalin®), which is also a member of the amphetamine 
family), narcolepsy and exogenous obesity (Halkitis et al., 2001; Greenhill et al., 2002; 
Fowler et al., 2007; Kish 2008). The L-isomer of methamphetamine is also used as a 
decongestant as previously mentioned (Fowler et al., 2007; Mendleson et al., 2008; Dufka et 
al., 2008).    
 
 






1.3.5 Routes of administration 
Illicit methamphetamine occurs in various forms; powder, tablets and translucent crystals 
resembling rock candy or salt (Halkitis et al., 2001). There are numerous routes of 
methamphetamine administration, including intravenous injection, inhalation, smoking and 
ingestion (Halikitis et al., 2001). The crystalline form of methamphetamine or “crystal meth” 
is the more commonly abused form of the drug and is responsible for a more rapid intense 
stimulant effect when it is smoked (Kish, 2008). 
The smoking and intravenous injection of methamphetamine produces the fastest rates of 
absorption, with a lag time of approximately 7-10 seconds when smoked and 15-30 seconds 
when injected (Halikitis, 2001). Inhalation and intramuscular injection produce slower 
absorption rates with lag times approximating 3-5 minutes when inhaled and 5 minutes when 
administered intramuscularly (Halikitis, 2001). The oral ingestion of methamphetamine in its 
tablet form produces the slowest rate of absorption, with a lag time of approximately 20-30 
minutes (Halikitis, 2001). 
The effects of the drug can last in the region of 8 – 24 hours after administration depending 
on the amount used and the route of administration (Halikitis, 2001).  
1.3.6 Pattern of use and drug effects 
It is the immediate psychological effects of methamphetamine that gives it its tremendous 
potential for abuse due to the “rush” given to the user upon administration (Logan, 2002; 
Lineberry et al., 2006) Methamphetamine, even in small amounts, leads to potent autonomic 
and central nervous system effects (Halikitis et al., 2001). Methamphetamine has become the 
psychostimulant of choice due to its significantly higher elimination half-life as opposed to 
other stimulants such as cocaine and ecstasy, leading to these positive behavioural and 
psychological effects lasting substantially longer than with other drugs (Tominaga et al., 
2004; Barr, 2006). The effects can last 6 – 12 hours longer than cocaine, depending on the 
dose and the pH of the urine (Tominaga et al., 2004). Methamphetamine also differs from 
other stimulants in that it has relatively high lipid solubility, allowing for more rapid transfer 
of the drug across the blood brain barrier, thereby enhancing the drugs’ central effects (Barr 
et al., 2006).  
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The incentives for the initial use of methamphetamine vary widely, from shift workers 
wanting to combat fatigue, students to aid in increase concentration and studying, teenagers 
and others who use it as a dietary aid to accelerate weight loss, to the purely hedonistic 
purpose and recreational use of the drug (Logan, 2002). It is this purpose for use that will 
ultimately dictate the pattern of use. Regardless of the initial motivation, habituation to the 
central nervous system effects of the drug develops quickly, and if use is continued the user 
generally deteriorates into binge using (Logan, 2002).  
Although not a common pattern of abuse, the administration method that receives the greatest 
amount of research is that of the single therapeutic dose of methamphetamine (5-10mg) 
(Logan, 2002). It is at this dose that the user experiences the alerting and anorectic effects, 
feelings of euphoria and well-being, increased energy, elimination of fatigue and drowsiness, 
increased libido, a general increase in psychomotor activity, an alteration to self-esteem and 
self-confidence, as well as intensifying emotions and suppressing the appetite (Derlet et al., 
1990; Halikitis et al., 2001; Logan, 2002; Tominaga et al., 2004; Barr et al., 2006; Lineberry 
et al., 2006; Schifano et al., 2007; Buxton and Dove, 2008; Phillips et al., 2008; Shoptaw et 
al., 2008). In men, ejaculation is delayed and the intensity of the orgasm is enhanced which, 
coupled with the increase in libido associated with methamphetamine use, gives it its popular 
reputation as the “sex drug” (Logan, 2002; Buxton and Dove, 2008; Shoptaw et al., 2008). As 
well as alerting symptoms, due to the stimulating effects on the central nervous system, the 
user may also experience restlessness, increased irritability, insomnia, aggressiveness, 
paranoia, anxiety, dizziness, overstimulation, mild confusion and in rare instances panic or 
psychotic states (generally in individuals predisposed to schizophrenia) (Halikitis et al., 2001; 
Logan, 2002; Tominaga et al., 2004; Buxton and Dove, 2008; Shoptaw et al., 2008). 
1.3.7 Metabolism and clearance of methamphetamine 
Methamphetamine undergoes phase I metabolism by N-demethylation to amphetamine via 
the cytochrome P4502D6 isoenzyme system, which also plays a role in the aromatic 
hydroxylation of methamphetamine (Lin et al 1997; Logan, 2002; Dostalek et al., 2007). The 
amphetamine is then extensively metabolized to a variety of metabolites including 
norephedrine and p-hydroxyamphetamine, both of which are pharmacologically active, and 
may be glucuronidated prior to excretion (Logan, 2002). Methamphetamine undergoes four 
different metabolic processes in both humans and rats, namely, aromatic or p-hydroxylation, 
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aliphatic or β-hydroxylation, N-demethylation and deamination (Figures 13 and 14. Caldwell 
et al., 1972; Musshoff 2000; Kanimori et al., 2005; Dostalek et al., 2007). In vivo studies in 
humans show that the main primary metabolic reactions are aromatic hyroxylation and N-
demethylation and these processes account for the production of the p-hydroxy derivative, p-
hydroxymethamphetamine, and amphetamine respectively, which make up almost 50% of all 










Figure 13: Main metabolic pathways of methamphetamine and amphetamine in man: 
(A) methamphetamine; 
(B) amphetamine; (C) 4-hydroxymethamphetamine; (D) 4-hydroxyamphetamine; 
(E) phenylacetone(phenyl-2-propanone); (F) norephedrine; (G) 4-hydroxynorephedrine; 
(H) benzoic acid; (I) glycine; (J) hippuric acid. 
(Musshoff et al., 2000) 
There is a distinct difference between methamphetamine metabolism in man and rats, with 
the primary metabolic reaction in rats being aromatic hydroxylation (Caldwell et al 1972). In 
a study by Caldwell, the urine of 3 rats and 2 men were analysed and it was shown that the 
main metabolite that is found in the urine of man is unchanged methamphetamine whereas in 
rats unchanged drug only accounts for approximately 1/10 of dose excreted, with 3% of urine 
metabolites appearing as amphetamine in both man and rat. Both man and rat were shown to 
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excrete norephedrine derivatives, d-hydroxyephedrine in the rat and norephedrine in man 
(Caldwell et al., 1972; Musshoff 2000).  
 
Figure 14: Summary of the metabolic pathway of methamphetamine in the rat 
(Kanimori et al., 2005) 
 
1.3.8 Peripheral effects of methamphetamine  
The peripheral effects of methamphetamine are mainly a result of its actions as an α-, β1- and 
β2 adrenergic agonist (Logan, 2002). The effects of methamphetamine on epinephrine and 
norepinephrine release by the adrenal glands are characteristic to those of a fight or flight 
response (Barr et al., 2006; Schifano et al., 2007). The effects mediated by the α-receptors 
include mydriasis (pupil dilation), vasoconstriction, bronchial muscle dilation, bladder 
contraction and urinary retention, stomach cramps, hyperthermia, muscle and skin tremors 
and coronary dilation (Halkitis et al., 2001; Logan, 2002; Barr, 2006; Schifano et al., 2007). 
Also typical to an adrenaline response, methamphetamine causes acceleration in heart rate, 
hyperglycaemia, hypertension, specifically an increase in venous blood pressure due to the 






2002; Tominaga et al., 2004; Barr, 2006). Dry mouth, perspiration or chills are also 
sometimes experienced by the user (Halkitis et al., 2001). 
The toxic effects of methamphetamine is related to multiple factors which include among 
others, oxidative stress with the production of oxygen and nitrogen reactive species, aberrant 
catecholaminergic transmission, excitotoxicity, mitochondrial dysfunction, and apoptosis 
(Williams et al., 2003; Darke et al., 2008; Sharma et al., 2008). The neurotoxic effects of 
methamphetamine involves the degeneration of the nerve terminals of dopamine and 
serotonin that are found in the frontostriatal region, resulting in the long lasting depletion of 
these monoamines and in the alteration in the regulation of these systems (Darke et al., 2008). 
Due to the oxidative stress mechanism of methamphetamine neurotoxicity, the use of 
selective antioxidants may prove to be neuroprotective (Darke et al., 2008). 
Methamphetamine causes intoxication by potentiating presynaptic nerve terminals to release 
catecholamine neurotransmitters norephinephrine and dopamine, causing the stimulation of 
post-synaptic receptor and inhibiting their reuptake, increasing their levels in the synaptic 
space (Tungtananuwat et al., 2009).  
Chronic use of methamphetamine severely affects the cardiovascular system with premature 
and accelerated development of artherosclerosis leading to an increased risk of myocardial 
infarction (Buxton and Dove, 2008; Darke et al., 2008; Shoptaw et al., 2008). Chronic use 
also leads to ventricular hypertrophy and this can predispose the user to methamphetamine-
induced myocardial ischemia and/or arrhythmias (Buxton and Dove, 2008; Darke et al., 
2008; Shoptaw et al., 2008). 
The physical manifestations of methamphetamine abuse include severe weight loss, dental 
decay and dry mouth known as “meth mouth” and scabbed skin, due to psychosis at high 
doses of the drug whereby the user has the persistent feeling of insects crawling on them and 
constantly scratching and picking at their skin (Schifano et al., 2007; Buxton and Dove, 
2008). 
1.3.9 Central effects of methamphetamine 
The effect profile of methamphetamine is very complex, with acute low dose administration 
exerting stimulant, alerting effects, with progressively more disorienting effects on cognition, 
reasoning and psychomotor ability occurring with increasing dose and duration of drug use 
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(Logan, 2002; Tominaga et al., 2004). During withdrawal from methamphetamine, a 
depressant-like profile occurs, including anhedonia and decreased motivation, which is often 
compounded by delusions and psychotic episode, especially after high-dose or chronic use 
(Logan, 2002; Barr et al., 2006). 
The primary mechanism by which amphetamines’ exert their effects is by increasing the 
levels of extracellular monoamine neurotransmitters within the central nervous system (Barr 
et al., 2006; Kish, 2008). The sympathetic neurotransmitters particularly targeted are 
serotonin, the catecholamines norepinephrine and epinephrine, with the principle monoamine 
being dopamine. The structural similarities to methamphetamine and these neurotransmitters 
are clear (Figure 15, Halikitis et al., 2001; Logan, 2002; Barr et al., 2006; Kish, 2008).  
Studies have shown that with a single injection of methamphetamine there is a marked 
increase in dopamine, serotonin and norepinephrine in the dopamine-rich subdivisions of the 
striatum such as the caudate, putamen, ventral striatum (the nucleus accumbens is included in 
this brain area) as well as in the pre-frontal cortex (Kish, 2008; Herrold et al., 2008). It is the 
enhanced release of norepinephrine from their central neurons that is responsible for the 
alerting and anorectic effects of amphetamines, including methamphetamine, and together 
with the release of dopamine from dopaminergic nerve terminals that is responsible for the 
locomotor stimulating effects of the drug (Logan, 2002). The stereotyped repetitive behaviour 
that is associated with high dose methamphetamine use is also a feature of dopamine release, 






Figure 15: Structures of the sympathomimetic methamphetamine and the neurotransmitters whose 
release they promote.  
(Adapted from Logan 2002) 
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The amphetamines’ potent stimulating effects appear to result by promoting the release of 
these biogenic amines via various mechanisms including; promoting their release from stores 
in the nerve terminals, the reverse transport of the neurotransmitter through the plasma 
membrane transporters and the redistribution of catecholamines from synaptic vesicles to the 
cytosol (Logan, 2002; Nagai et al., 2005; Barr et al., 2006). Additionally, amphetamines 
block the activity of monoamine transporters and decrease the expression of dopamine 
transporters at the cell surface (Figure 16; Barr et al., 2006). Evidence also shows that 
amphetamines increase cytosolic levels of monoamines by the inhibition of monoamine 
oxidase (MAO) and by stimulating the activity and expression of tyrosine hydroxylase (TH) 










Figure 16: Physiological mechanisms by which methamphetamine increase synaptic levels of 
monoamines, principally dopamine (DOPA): (1) redistribution of catecholamines from synaptic 
vesicles to the cytosol; (2) reversing transport of neurotransmitter through plasma membrane 
transporters; (3)blocking the activity of monoamine transporters , (3) decreasing expression of 
dopamine transporters at the cell surface (4) increasing cytosolic levels of monoamines by inhibiting 
the activity of monoamine oxidase (MAO) (5) increasing activity and expression of the tyrosine 
hydroxylase 
DAT = dopamine transporter; vMAT = vesicular monoamine transporter. 
(Adapted from Barr et al., 2006) 
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As previously stated, methamphetamine increases the concentration of extracellular 
dopamine in part by interfering with the dopamine transporter as well as increasing the 
amount of tyrosine hydroxylase in the mesolimbic dopamine system (Nagai et al., 2005; 
Rocha et al., 2008). Tyrosine hydroxylase is the rate limiting enzyme in dopamine synthesis 
and it is responsible for the conversion of L-Dopa to dopamine (Serretti et al., 1998, Figure 
17). Therefore by potentiating its increase; methamphetamine increases dopamine levels 
within the mesocorticolimbic system (Rocha et al., 2008, Figure 17). Within the nucleus 
accumbens methamphetamine acts as a potent substrate for dopamine transporters and cause 












Figure 17: Illustration of the dopamine biosynthetic pathway. The effect of methamphetamine on this 
pathway is shown in red 
(Adapted from ww2.coastal.edu/.../molecules/molecules.html) 
 
Under normal conditions vesicular monoamine transporter-2 (VMAT2) transports 
cytoplasmic dopamine into reserpine-sensitive tubulovesicular organelles within the dendrites 
(Dobbs et al., 2008). This transport results in a decrease in cytoplasmic dopamine 




methamphetamine, its lipophilicity facilitates its diffusion into the dendrite (Dobbs et al., 
2008). This causes a disruption of VMAT2 therefore preventing the restoration of dopamine 
into vesicles (Dobbs et al., 2008). The resultant build-up of cytoplasmic dopamine causes a 
reversal of dopamine transport on the dendrites and induces somatodendritic release of 
dopamine into the synapse (Dobbs et al., 2008).  
 
In summary, methamphetamine is a stimulant drug belonging to the amphetamine family of 
drugs, whose global abuse has become an alarming problem. This easily synthesized drug can 
be administered in various ways, such as inhalation/snorting, injection, ingestion and 
smoking. The administration of methamphetamine results in a potent “rush”, which 
contributes to its reinforcing properties and increased potential for abuse. Peripheral effects 
of methamphetamine mirror those of a sympathetic “flight or fright’ response, due to its 
agonist effects on β1 and β2 adrenergic receptors. Centrally, acute low dose administration 
produce stimulatory and alerting effects, while progressively causing disorienting effects on 
cognition and reasoning with chronic use at higher doses. Methamphetamine administration 
also exerts effects within the mesolimbic dopaminergic system, increasing extracellular 
dopamine concentration within this circuit. This effect is brought about by 
methamphetamine’s ability to reverse VMAT, and increase the concentration of TH in the 
mesolimbic dopaminergic neurons. This increase in dopamine transmission is thought to play 
















1.4. Vasopressin and Oxytocin 
 
Tolerance, dependence and addiction to drugs such as methamphetamine may involve 
mechanisms of neuroadaptation that relates to learning and memory, at both a cellular as well 
as a system level (Gimpl et al., 2001). Within the paradigm of learning and memory, some 
interest has been shown in the involvement of neurohypophyseal hormones vasopressin and 
oxytocin in this area of neuroscience (Engelmann et al., 1996). 
 
1.4.1 Biosynthesis  
Vasopressin and oxytocin are nonapeptide hormones that are synthesized primarily within 
magnocellular neurons. Their cell bodies are located in the paraventricular and supraoptic 
nuclei in the hypothalamus (Alescio-lautier et al., 2000; Dyatkin et al., 2002). They are made 
up structurally of nine amino acids with a disulphide bridge between two cytseine residues at 
the 1 and 6 positions. (Gimpl et al., 2001; Holmes et al., 2003; Caldwell et al; 2008) 
Oxytocin and vasopressin share an 80% homology, differing in two amino acids at positions 
3 and 8. Vasopressin contains phenylalanine at position 3 and arginine at position 8, and 
oxytocin has isoleucine at position 3 and leucine at position 8 (Figure 18, Gimpl et al., 2001; 
Holmes et al., 2003; Caldwell et al., 2008). The neuropeptides are synthesized from large 
precursor molecules which are processed to biologically active peptides via post translational 
processing. This occurs within the neurosecretory vesicles into which it is packaged (Gimpl 
et al., 2001; Heinrichs et al., 2004; Landgraf et al., 2004).  
 
 
Figure 18: Amino-acid structure of Vasopressin and Oxytocin 





1.4.2 Vasopressin receptors and peripheral function 
 
Vasopressin, or anti-diuretic hormone as it is also known, exerts both peripheral and central 
function via its 3 receptor subtypes, namely V1a, V1b and V2 receptors (Lolait et al., 1995; 
Alescio-lautier et al., 2000; René et al., 2000; Holmes et al., 2003; Egashira et al., 2005; 
Caldwell et al., 2008). The endocrine effects of vasopressin are mediated through its 
interaction with these receptors on target organs (Alescio-lautier et al., 2000).  
 
All three vasopressin receptor subtypes belong to the family of guanine nucleotide – binding 
protein (G-protein) coupled receptors, which are characterized by 7 hydrophobic 
transmembrane domain ά helices joined by alternating intracellular and extracellular loops, 
an extracellular amino-terminal and a cytoplasmic carboxy terminal domain (De Wied, 1997; 
René et al., 2000; Holmes et al., 2003; Caldwell et al., 2008).  
 
V1a and V1b receptors act via Gq/11 coupling, which results in the stimulation of 
phospholipase C, which in turn generates the second messengers inositol triphosphate (IP3) 
and diacylglycerol (DAG) (Howl et al., 1995; Landgraf et al., 1995; Lolait et al., 1995; 
Alescio-lautier et al., 2000; Holmes et al., 2003; Caldwell et al., 2008). V1a receptor activity 
is involved predominantly within the cardiovascular systems, but also plays a role in 
modulating endocrine systems and carbohydrate metabolism (Howl et al., 1995; Lolait et al., 
1995; Alescio-lautier et al., 2000; René et al., 2000; Caldwell et al., 2008). 
 
V2 receptors stimulate adenylate cyclase through coupling with Gs proteins, thereby 
increasing cyclic adenosine monophosphate (cAMP), which connect to various cellular 
mechanisms, including ion channels, transcription factors and metabolic enzymes (Lolait et 
al., 1995; Alescio-lautier et al., 2000; René et al., 2000; Holmes et al; 2003; Caldwell et al., 
2008). V2 activity plays an important role in the regulation of plasma osmolality and volume, 
working in the collecting ducts of the kidney to promote water reabsorption (Hirasawa et al., 
1994; Ishunina et al., 1999; Dyatkin et al., 2002). 
  
1.4.3 Peripheral effects of oxytocin 
Oxytocin that is released as part of the hypothalamo-neurohypophyseal system, functions 
primarily in the peripheral reproductive tissues, and plays a role in the processes of lactation, 
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parturition and sexual behaviour, (Ishunina et al., 1999; Ivell et al., 1999; Gimpl et al., 2001; 
Holmes et al., 2003; Heinrichs et al., 2004; Ross et al., 2009).  
Oxytocin exerts its effects via interactions with its receptor, which, like vasopressin, belongs 
to the G-protein coupled receptor family (René et al., 2000; Gimpl et al., 2001; Marazziti et 
al., 2006).  It acts in the same manner as vasopressin V1 receptors, i.e. coupling via Gq/11 
class of proteins and activating phospholipase C to result in the formation of IP3 and DAG 
(Gimpl et al., 2001).    
1.4.4 Central distribution of vasopressin and oxytocin receptors and fibres 
 
In addition to the magnocellular projections making up the hypothalamo-neurohypophyseal 
pathway, oxytocin and vasopressin are released centrally into the brain by parvocellular 
neuron projections, to the median eminence as part of the hypothalamo-pituitary adrenal 
system as well as to other discrete brain areas (Engelmann et al., 1997; Kovács et al., 1998; 
Ishunina et al., 1999; Alescio-lautier et al., 2000). This indicates both peripheral and central 
functions for these neuropeptides (Kovács et al., 1998; Ishunina et al., 1999; Alescio-lautier 
et al., 2000; Klimkiewicz, 2001).  
 
Due to the wide distribution of oxytocin and vasopressin within the brain, they have been 
classified as serving both an endocrine and a neurotransmitter or neuromodulator function 
(Howl et al., 1995; Lolait et al., 1995; Engelmann et al., 1996; Boccia et al., 1998; Kovács et 
al., 1998; Ishunina et al., 1999; Heinrichs et al., 2004; Pittman et al., 2005). Unlike classical 
neurotransmitters that can only be released at the synaptic cleft, oxytocin and vasopressin can 
be released from the axon terminals as well as the dendrites and soma of hypothalamic 
neurons (Engelmann et al., 1997; Ross et al., 2009). They can therefore diffuse through to the 
extracellular space and achieve widespread distribution due to their long half–life (Landraf et 
al., 2004; Ross et al., 2009). The central effects of vasopressin and oxytocin may include 
various autonomic, endocrine and behavioural effects, and may be mediated by fragments 
and derivatives of the neuropeptide as well as the whole, as opposed to peripheral effects, 
which require the entire molecule (Van Heuven-Nolsen et al., 1984; Engelmann et al., 1996; 




Extrahypothalamic vasopressin is seen in the highest concentrations within the supraoptic and 
the suprachiasmatic nuclei, with substantial levels also detected in the septum and the locus 
coeruleus (Caldwell et al., 2008; Koob, 2008). Vasopressinergic fibres have also been 
localized in various cerebral regions, from the olfactory bulb to the spinal cord, the septal 
region, the bed nucleus of the stria terminalis and the medial amygdaloid nucleus (Alescio-
lautier et al., 2000; Caldwell et al., 2008; Koob, 2008). Vasopressin V1 receptor binding sites 
generally correspond with vasopressinergic projection sites, but are also highly expressed in 
the extended amygdala of the rat, with high concentrations in the lateral and supracapsular 
bed nucleus of the stria terminalis (BNST), central nucleus of the amygdala and the shell of 
the nucleus accumbens (Koob, 2008). More specifically, V1b receptors are highly expressed 
in areas such as the hypothalamus, hippocampus and cerebral cortex (Egashira et al., 2005). 
The V1b receptor subtype is also in the anterior pituitary gland, where it mediates the role of 
extrahypothalamic vasopressin in the potentiation of corticotrophin releasing hormone, and 
the subsequent stimulation of the release of adrenocorticotrophin hormone (Lolait et al., 
1995; Alescio-lautier et al., 2000; René et al., 2000; Caldwell et al., 2008).  
 
Within the brain vasopressin carries out numerous functions such as thermoregulation, 
regulation of blood pressure, brain development and circadian rhythm, cardiovascular 
homeostasis, regulation of aggression, certain aspects of pair bonding, social recognition, 
behavioural regulation, but in particular it is involved in learning and memory processes 
(Walter et al.,1978; Kovács et al.,1979; Biegon et al.,1984; Van Heuven-Nolsen et al.,1984; 
Lolait et al.,1995; Engelmann et al.,1996; Boccia et al.,1998; Ishunina et al.,1999; Alescio-
lautier et al.,2000; Pittman et al.,2005; Caldwell et al.,2008).  
 
Vasopressin has been shown to exert a long-term effect on the maintenance of learnt 
responses by facilitating consolidation, storage and retrieval of memory (Kovács et al., 1979; 
De Wied, 1997; Alescio-lautier et al., 2000; Heinrichs et al., 2004). This long-term 
facilitatory effect of vasopressin on memory was elucidated in tests of active and passive 
avoidance, with an increase in latency time observed upon both intraventricular and 
subcutaneous administration of vasopressin (Van Ree et al., 1985; De Wied et al., 1991; De 




The brain structures involved in the effects of vasopressin on learnt behaviours are the areas 
innervated by extrahypothalamic vasopressinergic pathways, specifically those within the 
limbic structures such as the septum, hippocampus and the amygdala, with V1a receptors 
found in the hippocampus (Biegon et al., 1984; De Wied, 1997; Alescio-lautier et al., 2000). 
The hippocampus and its related temporal-lobe areas play a pivotal role in memory formation 
and is one of the primary central targets for the memory enhancing effects of vasopressin, 
whether administered subcutaneously or intracerebroventricularly (Alescio-lautier et al., 
2000; Klimkiewicz, 2001).  
 
This effect within the limbic system may have a correlation with the enhancing effect that 
vasopressin has on catecholamine turnover in the hippocampal dendate gyrus, the dorsolateral 
septum and the nucleus of the tractus solitarius (Kovács et al., 1979; Biegon et al., 1984; Van 
Heuven-Nolsen et al., 1984; Landgraf et al., 1995). It is suggested that vasopressin acts more 
specifically on the utilization of noradrenaline in terminal areas of the coeruleotelencephalic 
noradrenaline system (Kovács et al., 1979; Biegon et al., 1984; Van Heuven-Nolsen et al., 
1984).  
 
The effect of vasopressin on memory may also be explained by its excitation of hippocampal 
and septal neurons, where vasopressin enhances the response of neurons to glutamate. This 
action of the hormone is proposed to serve as a neuromodulator for excitation in the limbic 
midbrain (De Wied, 1997). An increase in the slope and amplitude of field EPSPs in the 
dendate gyrus was seen in the presence of calcium, and this was induced by nanomolar 
concentrations of vasopressin, indicating a potential role of vasopressin in long-term 
potentiation (De Wied, 1997).  
 
Oxytocin fibres and nerve endings have been identified in numerous parts of the brain 
including the dorsomedial hypothalamic nucleus, thalamic nuclei, dorsal and ventral 
hippocampus, subiculum, entorhinal cortex, medial and lateral septal nuclei, amygdala, 
olfactory bulbs, mesencephalic central grey nucleus, substantia nigra, locus coeruleus, raphe 
nucleus and nucleus of the tractus solitarius (Gimpl et al., 2001). 
 
It is apparent from the wide distribution of oxytocin fibres in the brain that it has many 
central functions, including thermoregulation, social interaction, analgesia, gastric motility, 
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osmoregulation, inhibition of the stress response, with the primary functions being social 
attachment and the facilitation of the maternal behaviour required for the survival of 
offspring (Ishunina et al., 1999; Gimpl et al., 2001; Egashira et al., 2005; Heinrichs et al., 
2004; Ross et al., 2009). Rodent studies have shown that oxytocin is important in facilitating 
the onset of maternal behaviour, however is not required for its maintenance as 
administration of an oxytocin antagonist did not inhibit maternal behaviour that has already 
been established (Gimpl et al.,2001; Ross et al., 2009).  
 
In learning and memory, the general understanding is that oxytocin has an effect opposite to 
that of vasopressin, in that it attenuates the consolidation and retrieval of memory and having 
an overall amnesic effect (Kovács et al., 1979; De Wied, 1997; Ishunina et al., 1999; 
Heinrichs et al., 2004). The sites of action for these learning and memory effects are within 
the limbic areas of the brain, the amygdala, septum, some thalamic areas and the 
hippocampus, where oxytocin receptors have been identified (De Wied, 1997; Heinrichs et 
al., 2004).  
 
It has been suggested that the general theory with regards to vasopressin and oxytocin in 
learning and memory is subject to change dependent on specific behavioural tests, the 
specific administration or endogenous stimulation of the neuropeptide as well as the specific 
brain areas involved (Kovács et al., 1979; Sahgal et al., 1984; Van Ree et al., 1985; 
Engelmann et al., 1996; De Wied, 1997; Boccia et al., 1998; Heinrichs et al., 2004).  
 
In summary, vasopressin and oxytocin are neurohormones synthesized within magnocellular 
neurons, the cell bodies of which are found in the hypothalamus. They exert peripheral 
effects, and have a wide distribution within the brain, leading them to be classified as both 
endocrine hormones and neurotransmitters. Both vasopressin and oxytocin have been shown 
to play a role in learning and memory processes, with vasopressin having a facilitatory effect 
and oxytocin having an inhibitory effect. These roles in learning and memory have prompted 
interest in their possible roles in the addictive state, which has been linked to 






1.5 Aim of the present study 
 
Maladaptive processes in learning and memory have been implicated as a possible 
mechanism behind the development of addiction (Kelly, 2004; Saal and Malenka, 2005). To 
this end we developed an interest into a possible role for vasopressin and oxytocin in the drug 
addiction process. As such the present study wished to address the following questions: 
1. Does vasopressin antagonism block the development of drug seeking behaviour 
during addiction? 
2. Does oxytocin administration block the development of drug seeking behaviour 
during addiction? 
3. If yes, what are the mechanisms by which both these hormones would exert their 
effects? 
Our experimental approach to answer these questions briefly entailed: 
1. The establishment of a rat model displaying properties of drug addiction. Here we 
treated male Sprague-Dawey rats with methamphetamine and assessed their addictive 
behaviour using a place preference paradigm. 
2. The role of vaspressin antagonism was determined by treating “addicted” rats during a 
drug seeking period with vasopressin V1b antagonist, SSR 149415. 
3. In parallel but independent experiments “addicted” rats were similarly treated with 
oxytocin. 
4. Dopamine levels in the striata and the expression of CREB in the hippocami of the 
same animals were subsequently measured in our investigation into possible 
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Abstract 
Methamphetamine is a highly addictive stimulant drug whose illicit use and resultant 
addiction has become an alarming global phenomenon. The mesolimbic dopaminergic 
pathway has been shown to be fundamental to the establishment of addictive behaviour. This 
pathway, as part of the reward system of the brain, has also been shown to be important in 
classical conditioning, which is a learnt response. Within the modulation of learning and 
memory, the neurohypophyseal hormones vasopressin and oxytocin have been reported to 
play a vital role, with vasopressin exerting a long- term facilitatory effect and oxytocin 
exerting an inhibitory effect. Therefore we adopted a conditioned place preference model to 
investigate whether vasopressin V1b receptor antagonist SSR 149415 or oxytocin treatment 
would cause a decrease in the seeking behaviour in a reinstatement paradigm. Behavioural 
findings indicated that methamphetamine induced a change in the place preference in the 
majority of our animals. This change in place preference was not seen when vasopressin was 
administered during the extinction phase. On the other hand the methamphetamine-induced 
change in place preference was enhanced during the reinstatement phase in the animals that 
were treated with oxytocin. Striatal dopamine levels were determined, as methamphetamine 
is known to increase dopamine transmission in this area. Significant changes in dopamine 
levels were observed in some of our animals. Rats that received both methamphetamine and 
oxytocin had significantly higher striatal dopamine than those that received oxytocin alone. 
Western blot analysis for hippocampal cyclic AMP response element binding protein (CREB) 
was also conducted as a possible indicator of glutamatergic NMDA receptor activity, a 
pathway that is important for learning and memory. The Western blot analysis showed no 
changes in hippocampal pCREB expression. Overall our data led us to conclude that 
methamphetamine treatment can change place preference behaviour in rats and that this 





Drug addiction remains one of the biggest health and social problems worldwide (Buxton and 
Dove, 2008). South Africa is not excluded from this statistic with continuing escalation in the 
use of illicit drugs especially between the ages of 15 – 25 years being reported by the South 
African Community Epidemiology Network on Drug Use (SACENDU Report June 2011). 
Addiction is said to be a chronically relapsing disorder that is characterized by a compulsion 
to take a drug, a lack of control in limiting this intake and the withdrawal of the drug 
resulting in the development of a negative emotional state associated with severe signs of 
discomfort (Koob, 2000; Shippenberg et al. 2007; Koob and Volkow, 2010).  
Once addiction is established, it tends to follow a chronic course consisting of periods of 
abstinence that are usually followed by relapse (Hyman and Malenka, 2001). Repeated 
exposure to drugs of abuse may also produce tolerance in users, whereby molecular 
adaptations result in a diminished effect of the drug despite a constant dose, requiring the user 
to increase their dose to achieve the same effect (Roberts and Koob, 1997; Hyman and 
Malenka, 2001). This increase in dosage may lead to the exacerbation of the molecular 
changes that lead to addiction (Hyman and Malenka, 2001).  
It is now commonly accepted that the mesocorticolimbic pathway plays a critical role in 
diverse motivational processes including drug reward and addiction-like behaviour (Dobbs et 
al. 2008; Herrold et al. 2008). Each of the structures within this pathway in particular the 
ventral tegmental area, the nucleus accumbens and the ventral pallidum has all been shown to 
be critically involved in psychostimulant (such as methamphetamine) drug-induced 
behaviour in rats (Herrold et al. 2008). The cortical and limbic areas of the brain, which 
subsequently receive projections from these areas, are important for the expression of 
emotions, reactivity to conditioned cues, planning and judgement, and have therefore been 
implicated in reward (Tomkins and Sellers 2001). 
In general addictive behaviour is characterised by drug-induced dopamine release leading to 
compulsive drug use followed by a period of drug absence leading to the development of 
drug seeking behaviour. It has been postulated that cellular changes at the level of the 
synapse may underlie the behavioural changes associated with addiction (Hyman, 2005). 
Long term potentiation and depression are two phenomena that have been associated with 
synaptic plasticity (Calabresi et al. 2007; Kauer et al. 2007) and may therefore be suitable 
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candidates to mediate such synaptic alterations. LTP and learning within the hippocampus, 
via glutamate receptor activation, results in the downstream activation of cyclic adenosine 
monophosphate (cAMP) and cAMP response element-binding protein (CREB) mediated 
transcription, a pathway whose upregulation is one of the best established adaptations to 
chronic exposure to drugs of abuse (Nestler, 2001; Kopnisky and Hyman, 2002; Chao et al. 
2004). CREB acts as an important transcription factor and regulates gene expression in 
learning and memory circuits via the cAMP pathway (Nestler, 2001; Mizuno et al. 2002; 
Fanselow et al. 2005; Hyman, 2006). 
Since LTP and CREB activation are important in learning and memory, and have been shown 
to be activated in response to drugs of abuse, it has been postulated that addictive behaviour 
may have elements of learning and memory underlying its development (Nestler, 2002; 
Kelley, 2004).  
Within the paradigm of learning and memory, much interest has been shown in the 
involvement of neurohypophyseal hormones vasopressin and oxytocin (Engelmann et al. 
1996). The general theory with regards to learning and memory is that vasopressin has a 
facilitatory and oxytocin an inhibitory effect on learning and memory. However this theory 
remains controversial and is subject to change dependent on specific behaviours as well as 
the specific brain areas being studied (Kovács et al. 1979; Sahgal et al. 1984; Van Ree et al. 
1985; Engelmann et al. 1996; de Wied, 1997; Boccia et al. 1998; Heinrichs et al. 2004). For 
instance the long term facilitatory effects of vasopressin on memory was elucidated in tests of 
active and passive avoidance, with an increase in latency time observed upon both 
intraventricular and subcutaneous administration of vasopressin (Van Ree et al. 1985; de 
Wied et al. 1991; de Wied et al. 1997; Engelmann et al. 1998; Klimkiewicz, 2001). Notably 
this effect was not seen in other memory tests such as water maze and hole-board tests 
(Klimkiewicz, 2001). Other studies have shown that oxytocin may reduce the abuse potential 
of many drugs, with administration of oxytocin resulting in the attenuation of tolerance 
development to morphine and heroin as well as decreasing the intravenous self-
administration of heroin in rats (Kovács et al. 1987; Gimpl et al. 2001; Marazziti et al. 2006; 
Qi et al. 2009; Carson et al. 2010). 
 The aim of the present study was therefore to investigate whether the administration of 
oxytocin and the vasopressin antagonist SSR 149415, could reverse methamphetamine-
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induced addictive behaviour in a conditioned place preference rat model. In the study 
dopamine levels in the striatum were also determined as a molecular indicator of the effect of 
methamphetamine administration. In addition the levels of cyclic AMP response element 
binding protein (CREB) in the hippocampus were assessed as an indirect indicator of the 
involvement of glutamatergic receptors in learning and memory processes associated with 
addictive behaviour.  
Materials and methods 
Animals 
Forty-eight male Sprague-Dawley rats ranging in weight from 200-250g were used. Animals 
were housed in the Biomedical Resource Centre at the University of KwaZulu-Natal, 
Westville campus under standard laboratory conditions of 23±2°C room temperature, 70% 
humidity and a 12hour day-night cycle with lights-on at 06h00. Food and water was made 
available ad libitum. Chemicals used in our protocol were SSR 149 415 (a gift from Sanofi-
Aventis), (+)-methamphetamine hydrochloride and oxytocin lyophilized powder, ~50 IU/mg 
solid, both of which were purchased from Sigma Aldrich, USA.   
Animals were randomly divided into 6 groups (n=8) and received the following treatment; 
Group 1 – saline; Group 2 – saline followed by SSR 149415 (the vasopressin V1b 
antagonist); Group 3 - saline followed by oxytocin; Group 4 – methamphetamine followed by 
saline; Group 5 - methamphetamine followed by SSR 149415; Group 6 - Methamphetamine 
followed by oxytocin. The Animal Ethics Subcommittee of the University of KwaZulu-Natal 
approved all procedures, which were all in accordance to the guidelines of the National 
Institutes of Health (Ethics clearance number 044/08/Animal). 
Apparatus 
A place preference box was used to condition the rats to methamphetamine. The box had 
dimensions of 45x45x45cm and was divided into two equally sized compartments by a 
sliding partition. Each compartment had distinct features. For instance the walls of one 
compartment had a black and white checked appearance while the walls of the other 
compartment remained plain black. Also, a wire mesh covered the floor of the checked 
compartment, while the other compartment floor remained smooth. The behaviour of the 
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animal in the two-compartment box was recorded and the time spent in each compartment 
was assessed at a later stage.  
Place Preference Procedure 
The place conditioning procedure used in this experiment included the (i) acquisition of 
Conditioned Place Preference -CPP- (consisting of three phases namely pre-exposure, 
conditioning phase and CPP test), (ii) extinction training and (iii) reinstatement (Mueller and 
Stewart, 2000; Zhou and Zhu, 2006; Qi et al. 2009, see Figure 1 for experimental outline).  
Acquisition 
Phase 1 - Each test animal received three pre-exposure tests before the experiment, in which 
they were allowed access to the entire apparatus for 15 min. The amount of time spent in each 
chamber was monitored and an average time taken from the three tests to determine the 
naturally preferred chamber for the animal.  
Phase 2 - On days 1, 3, 5, and 7, the rats in groups 2, 3 and 5 were given a dose of 
methamphetamine (2.5mg/kg, i.p.), and then placed into the less preferred chamber for 50 
min. Our dose was established from a dose dependent study conducted by DeMarco et al. 
(2009) where doses of 1, 2.5, 5 and 10mg/kg did not produce a dose-dependent change in 
place preference. As higher doses did not result in greater place preference changes, we 
decided to use  the moderate dose of 2.5mg/kg. In groups 1, 4 and 6 saline was injected on 
these days. On days 2, 4, 6, and 8, rats received an equivalent volume of 0.9% saline (1ml, 
i.p.) before being confined to the preferred compartment, for 50 min. This strategy was 
adopted to ensure that the association with the non-preferred chamber was indeed driven by 
methamphetamine. 
Phase 3 - On day 9, the sliding partition separating the two chambers was removed and the 
rats allowed free access to the entire apparatus for 15 min without any restriction. The 
amount of time spent in each chamber was recorded. 
Extinction 
After conditioning and the initial CPP test, from days 10 to 17, saline was alternate paired 
four times with each of the chambers, once per day, over 8 days.  
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The extinction phase of this model therefore allows for exposure to the place preference box 
during a period of abstinence. During this time of ‘sobriety’, we administered our treatments 
to determine whether established seeking behaviour could be attenuated, and relapse 
prevented.  
In groups 3 and 5 oxytocin (1mg/kg, s.c.) and SSR149415 (1mg/kg, s.c.) respectively was 
administered instead of saline during this extinction phase. The doses of oxytocin and SSR 
149 415 were established from studies by Cui et al (2001) and Feifel et al (2011), where 
subcutaneous dose of 1mg/kg oxytocin was seen to exert central effects. Most studies using 
SSR 149 415 administered doses i.p. so we used the same dose as for oxytocin.  On day 18, a 
second CPP test was performed.  
Reinstatement 
On the next day following the second CPP test (day19), the test animals were given a priming 
injection of methamphetamine (1mg/kg, i.p.) and 10 min later, the rats were allowed free 
access to the entire apparatus for 15 min. The priming dose used is in accordance with 
priming i.p. doses from previous studies (Rogers et al. 2008; Holtz et al. 2012). The amount 
of time spent in each chamber was once again recorded. Our protocol is a modified version of 
Zhou and Zhu (2006), where there was a 10 min interval after morphine injection before CPP 
testing. Research using methamphetamine tested for CPP immediately after priming 
injection; however the methamphetamine was administered i.c.v. (Carson et al, 2010). We 
therefore took into account that i.p. administration results in methamphetamine taking longer 
to reach the brain and exert its effects, and allowed for a 10 min interval so that maximal 





Figure 1: Outline of the 3 phase conditioned place preference protocol 
Tissue Collection 
On day 20, animals were sacrificed by decapitation, and their striatal  and hippocampal tissue 
were  harvested,snap frozen in liquid nitrogen, then stored in a biofreezer at -75°C. The tissue 
was later used for the analysis of dopamine and phosphorylated CREB (pCREB) levels 
respectively.  
Dopamine assay 
A commercial Dopamine ELISA kit (IBL International GMBH, Hamburg, Germany) was 
used to quantify dopamine concentration. Striatal tissue was thawed on ice and then 500µl of 
EDTA (1M)-HCl (0.1N) buffer was added. Samples were sonicated while on ice, for thirty 
seconds, using the Misonix Sonicator model XL2000-010 (USA). Sonicated samples then 
underwent centrifugation at 13500 rpm for fifteen minutes at 4ºC. The dopamine content of 
the supernatants was then determined by ELISA following the manufacturer’s protocol. 
Western blot 
Total hippocampus protein was extracted from each sample using Cytobuster™ (Calbiochem, 
UK) reagent, supplemented with protease inhibitors, as per manufacturer guidelines. Protein 
concentration was determined by the bicinchoninic acid assay (Sigma, Germany) and 
standardized to 1 mg/ml. Samples containing 40 µg of protein were boiled in Laemmli buffer 
for 5 minutes and then subjected to electrophoresis in 10% sodium dodecyl sulfate (SDS)-
polyacrylamide gels. Separated proteins were then electro-transfered to polyvinylidene 
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difluoride membranes (PVDF). After blocking with Tris-buffered saline (TBS) containing 
5% bovine serum albumin and 0.1% Tween 20, the membrane was immuno-probed with 
rabbit anti-p-CREB Ser133 (1: 500; Cell Signalling Technology, USA) overnight at 4°C. The 
PVDF membrane was then subjected to 5 washes (10 minutes each) with TBS containing 
0.1% Tween 20. The membrane was then exposed to secondary antibody (anti-rabbit-horse-
radish-peroxidase (HRP)-conjugate; 1:10, 000; Bio-Rad, USA) for 1 hour at RT. Anti-β-
actin-HRP (Sigma, Germany) was used for internal loading controls. After further washing, 
antigen-antibody complexes were detected by chemiluminescence using the Immune-star™ 
HRP substrate kit (Bio-Rad, USA). Chemiluminescent signals were detected with the 
UViTech Alliance 2.7 gel documentation system. Images were acquired and analyzed with 
UViTech Analysis™ image analysis software (UViTech, USA). Following densitometric 
analysis on sample bands and corresponding loading standards (B-Actin), mean relative band 
density was divided by mean relative band density of B-actin to obtain a normalised relative 
stimulation/inhibition of treated samples.  
Statistical Analysis 
Data was analysed using GraphPad Prism (version 5, San Diego, California, USA). All the 
data was tested for normality using the Kolmogorov-Smirnov test and some found to be not 
normally distributed. Subsequently all data was analysed using the non-parametric tests. For 
the behavioural data Friedman’ test (similar to parametric repeated measures ANOVA) was 
used to determine the presence of any significant differences between the test times. This was 
followed by the Dunn’s multiple comparison test. In the case of the dopamine levels and 
CREB expression levels the Kruskal-Wallis test was used to assess the significance of 
differences between groups. For the dopamine levels, this was then followed by Mann-
Whitney U test. Differences were considered significant when p values were < 0.05. In 
graphs the data is represented as mean ± SEM with medians reported in the figure legends. 
Results 
Behavioural tests 
Behavioural data is represented as a measure of time spent in the preferred side of the place 
preference box. Place preference behaviour in the control group administered with saline 
showed no significant difference in time spent in preferred side throughout the 3 phases 
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(Figure 2a). Similar results were seen in the groups receiving oxytocin and the vasopressin 
antagonist in the extinction phase (Figure 2b and 2c).  










Figure 2: Conditioned place preference behaviour in groups receiving saline in the acquisition 
phase and (a) saline, (b) the vasopressin antagonist SSR149415 or (c) oxytocin during the 
extinction phase. All animals received saline during the reinstatement phase. PT – pre test; 
Pst1 – post test 1; Pst 2 – post test 2; R - reinstatement 
Graph is presented as mean ± SEM (n=8) and was analysed using Friedman’s test. Respective 
medians are: Saline (PT – 515.8; Pst1 – 510.0; Pst2 – 501.5; R – 463.5) SSR 149415 (PT - 
376.7; Pst1 – 548.5; Pst2 – 563.0; R – 528.5) Oxytocin (PT – 588.2; Pst1 – 467.0; Pst2 – 
420.5; R – 266.5) 
Animals treated with methamphetamine and saline showed no significant differences in their 
pre-test, post-test and reinstatement times (Figure 3a). However in a separate experiment 
methamphetamine independently caused a significant reduction in time spent in the preferred 
side, i.e. a comparison between pre-test and post-test 1 (Figure 3b; p < 0.05) and this 
difference was partially blocked by subsequent treatment with SSR 149 415 during the 
extinction phase. These animals also did not show a change in their place preference during 
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significantly reduced the time spent by the animals in the preferred side (Figure 3c; p < 0.05). 
This significant reduction was not evident when animals were treated with oxytocin during 
the extinction phase, but was re-established during the reinstatement phase (Figure 3c).  




   
 




Figure 3: Conditioned place preference behaviour in groups receiving methamphetamine in 
the acquisition phase and (a) saline, (b) the vasopressin antagonist SSR149415 or (c) 
oxytocin during the extinction phase. All animals received methamphetamine during the 
reinstatement phase. PT – pre test; Pst1 – post test 1; Pst 2 – post test 2; R - reinstatement 
Graph is presented as mean ± SEM (n=8) and was analysed using Friedman’s test followed 
by Dunn’s multiple comparison test with p < 0.05 considered significant. Respective medians 
are: Saline (PT – 540.8; Pst1 – 530.5; Pst2 – 551.5; R – 407.5) SSR 149415 (PT – 551.7; Pst1 
– 327.0; Pst2 – 356.5; R – 344.0) Oxytocin (PT – 674.2; Pst1 – 497.0; Pst2 – 629.0; R – 
312.5) 
Figure 3a: no significance 
Figure 3b: *PT significantly different from Pst1 
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Striatal dopamine levels  
Five animals from the non-drug treated groups were randomly selected for ELISA analysis, 
while the five animals that best displayed seeking behaviour were chosen from the drug 
treated groups. Significant differences in striatal dopamine levels were observed between 
some of the oxytocin and methamphetamine treated groups (Figure 4). Saline treated animals 
that received either the vasopressin antagonist SSR 149415 or oxytocin showed no significant 
effect on striatal dopamine levels. However there was a significant difference in dopamine 
levels between the animals that received saline and oxytocin when compared to the 








Figure 4: Striatal dopamine concentrations per mg of tissue. Data is presented as mean ± 
SEM (n=5) and was analysed using Kruskal-Wallis test followed by the Mann-Whitney U 
test. Respective medians are: Saline – 0.036; SSR – 1.747; OXT – 0.284; Meth – 6.809; 
MSSR – 4.366; MOXT – 4.537 
 *OXT significantly different from MOXT, p = 0.0079. 
Saline – control group receiving saline  
SSR – control group receiving SSR 149 415 
OXT – control group receiving oxytocin 
METH – methamphetamine treated group receiving saline in extinction phase  
MSSR – methamphetamine treated group receiving SSR 149 415 in extinction phase MOXT 





























MSSR: Meth with SSR





























Hippocampal pCREB levels 
Western blot analysis of pCREB levels in the hippocampus revealed no significant 
differences in band intensity between all groups.  
 
Discussion 
Addiction is a major problem in the world today, impacting people on a physical, mental and 
in a social manner (Leshner, 1997). While there are many theories on the development of 
addiction, there exists a great amount of evidence linking addiction to the process of learning 
and memory (Hyman, 2005). To that end, we were interested in investigating the role of two 
neurohormones involved in learning and memory, vasopressin and oxytocin, within the 
addictive process. Our drug of interest was methamphetamine, a psychostimulant drug widely 
abused globally, and showing increased abuse here in South Africa in recent years (Salo et al. 
2008; Plüddemann et al. 2010). We adopted a place preference model of addiction consisting 
of 3 phases; acquisition to model the initial drug taking experience and subsequent addiction; 
extinction, to model a period of sobriety; and reinstatement, to model relapse in human 
addicts.  
 
Behavioural findings in our three control groups receiving saline in the acquisition phase 
showed no place preference changes in this phase, indicating the non-addictive properties of 
our vehicle. Similarly the administration of the oxytocin and the vasopressin antagonist 
SSR149415 during the extinction phase also did not result in significant changes in place 
preference behaviour, indicating that administration of oxytocin and the vasopressin 
antagonism had no effect on the determination of preference in non-addicted animals.  
 
Behavioural findings of the drug-treated groups showed mixed positive place preference 
behaviour. In the first set of experiments we were unable to show methamphetamine-induced 
changes in place preference behaviour.  This was mainly due to the variability in drug-
responses with 3 out of the 8 animals showing a marked preference change post drug 
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treatment and 1 animal spending nearly equal time in each compartment. These variances in 
behaviour resulted in non-significant differences and masked any indication of addictive 
tendencies in this group. However the data from this experiment did indicate that animal 
handling or the injection itself did not determine or influence behaviour. Animals in 
subsequent experiments consistently showed significant decreases in time spent in preferred 
compartments in post-test 1 as compared to the initial preference in the pre-tests. The 
variation in the animal responses to methamphetamine observed in the initial experiments is 
therefore difficult to explain. 
 
Those animals that exhibited a change in place preference to the drug-paired compartment 
indicated addictive behaviour and seeking tendencies. This finding is in agreement with that 
of others (Herrold et al. 2008). In the methamphetamine group treated with the vasopressin 
antagonist during the extinction phase, preference in post-test 2 showed no significant 
difference when compared to the initial preference of the animals. This was also seen in the 
reinstatement phase, where no significant decrease in place preference behaviour was noted 
in response to the priming dose of methamphetamine. This may indicate that administering a 
vasopressin antagonist may partially alter the seeking behaviour of the animals, as well as 
prevent reinstatement of drug seeking when given a priming dose of the drug. This is in 
accordance with a study by Zhou et al. (2008), where SSR149415 was used during the 
extinction phase of heroin addiction, and showed that V1b antagonism significantly reduced 
the reinstatement of drug taking in animals.  
 
Administering oxytocin during the extinction phase also attenuated the methamphetamine-
induced place preference change in animals. This suggested that oxytocin may have the 
potential to reverse drug-seeking behaviour, as was shown in a comparable study by Qi et al. 
(2009). Their findings indicated that intracerebrovascular administration of oxytocin 
facilitated the extinction of methamphetamine-induced place preference, and this was linked 
to its role as an amnesic neuropeptide. Interestingly our behavioural findings at reinstatement 
showed a significant decrease in time spent in preferred side, when compared to the pre-test 
times. This significant increase in time spent in the drug-paired compartment show that 
oxytocin was not effective in inhibiting the reinforcing effects of the priming dose of 
69 
 
methamphetamine. However, this result is in accordance with previous findings (Qi et al. 
2009), where the priming injection of methamphetamine reinstated the extinguished place 
preference behaviour.  
 
Dopamine levels in striatal tissue were evaluated between the various treatment groups. A 
significant difference in dopamine concentration was seen between the two oxytocin-treated 
groups that were pre-treated with saline and methamphetamine respectively. An increase in 
striatal dopamine content agrees with previous reports on the neurochemical effects of 
methamphetamine (Larsen et al. 2002; Pierce et al. 2006). Our data appears to be in line with 
findings suggesting a role for dopamine in addictive behaviour. The vasopressin antagonist 
SSR149415 did not alter dopamine levels significantly, indicating that vasopressin 
antagonism possibly does not act via dopamine in its partial blocking of methamphetamine-
induced addictive processes. A possible mechanism by which SSR149415 could have exerted 
its effects may involve suppression of the hypothalamo-pituitary-adrenal (HPA) axis. 
Vasopressin 1b receptors have been identified within the anterior pituitary gland, where it 
works synergistically with corticotropin-releasing hormone (CRH) to stimulate the release of 
adrenocorticotropic hormone (Tanoue et al. 2004; Dempster et al. 2007). CRH has been 
shown to play a role in cue- and methamphetamine- induced reinstatement (Moffett et al. 
2007). It is therefore possible that the antagonistic effect of SSR149415 on vasopressin V1b 
receptors may decrease the activity of CRH and the HPA axis, thereby decreasing 
methamphetamine-induced relapse behaviour. 
 
Following our behaviour results, where oxytocin increased place preference behaviour at 
reinstatement, we expected oxytocin to increase dopamine levels in the striatum. Although it 
has long been accepted that oxytocin cannot cross the blood brain barrier, it has been 
hypothesized that when administered subcutaneously, neuropeptides may pass in small 
amounts through the blood brain barrier and exert some central effects (Kovács et al. 1998; 
Cui et al. 2001). However, our observations show that oxytocin did not affect dopamine 
levels, with no significant difference when compared to the saline control group. Not 
surprisingly, oxytocin did not have an effect in decreasing dopamine levels in the 




Studies investigating the interaction between oxytocin and dopamine in relation to addiction 
have been limited, since the majority of experiments focused mainly on reproductive 
physiology (Cle´ment et al. 2008; Frye and Walf, 2010; Hedges et al. 2010) and 
maternal/social behaviour (Shahrokh et al. 2010; Robinson et al. 2011; Lenz and Sengelaub, 
2010). However there are reports implicating oxytocin in the reinforcing and long-term 
adverse effects of drug use (McGregor et al. 2008). Despite of the numerous studies 
implicating the involvement of oxytocin in dopamine-mediated addictive behaviour, its exact 
role and mechanism of action remains unclear. However a possible mechanism by which 
oxytocin increases the reinstatement of methamphetamine could be via its role in nitric oxide 
production. Oxytocin promotes the production of nitric oxide by protein kinase C- and 
calcium- induced activation of nitric oxide synthase (Zingg and Laporte, 2003). Nitric oxide 
is a highly diffusible neurotransmitter due to its gaseous nature and can readily act on a 
widespread area (Orsini et al. 2002), and has been implicated in cocaine-induce CPP as well 
as the development of methamphetamine reinstatement behaviour following priming 
injection (Li et al. 2002). The increase in nitric oxide levels due to oxytocin may result in the 
increase in reinstatement behaviours observed in our animals, although this remains for 
further investigation. 
 
We also investigated the effects of methamphetamine, SSR149415 and oxytocin on CREB 
expression levels in the hippocampus. Glutamate activation of N-methyl-D-aspartate 
(NMDA) receptors in the hippocampus triggers long-term potentiation and memory 
formation (Sarantis et al. 2009). Glutamate, binding to NMDA receptors, results in the 
downstream activation of CREB by promoting its phosphorylation at Ser133 (West et al. 
2002; Balazs, 2006).  This activated CREB is known to play a critical role in the synaptic 
plasticity associated with learning and memory, as well as addiction (Walters et al. 2003; 
Balazs, 2006). To that end, we conducted Western blot analysis to determine if the CREB 
pathway was activated and phosphorylated CREB was present within the hippocampus. 
Results showed no significant differences in pCREB levels in all groups, indicating that this 




In conclusion, we found some evidence that methamphetamine did induce seeking behaviour 
within a place preference model. Our findings suggest that vasopressin antagonism may play 
a role in decreasing reinstatement of methamphetamine behaviour, while oxytocin seems to 
exacerbate seeking tendencies and increase relapse behaviour. While we have observed that 
CREB activation in the hippocampus does not play a role in the effects of the vasopressin 
antagonist and oxytocin, neither do they alter dopamine levels in the striatum, and the exact 
mechanism by which they exerts their behavioural effects is unclear.  
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Drug addiction is a complex multi-factorial disease that occurs as a consequence of repeated 
pharmacological exposure to psychostimulant drugs causing pathological changes within the 
brain (Chao et al., 2004; Kalivas and O’Brien, 2008). Synaptic plasticity within learning and 
memory, and reward circuits have been implicated as part of the neuroadaptations that occur 
in addiction, with circuits usually linked with associative learning being recruited in response 
to the drug (Kopnisky and Hyman, 2002; Thomas and Malenka, 2003; Hyman, 2006).  
 
Neuropeptides oxytocin and vasopressin are involved in the process of learning and memory 
with vasopressin being facilitatory and oxytocin being inhibitory. These hormones have also 
been shown to play a role in addiction, with oxytocin showing a tendency to reduce the 
reinforcing properties of various drugs (Qi et al., 2009; Carson et al., 2010).  
 
However, few studies have been done to elucidate the molecular mechanisms by which these 
neuropeptides exert their effects. In addition, to the best of our knowledge there are no 
reports whether these hormones have any role in methamphetamine addiction. To this end we 
were interested in investigating whether vasopressin antagonism and oxytocin treatment 
would have any beneficial effects in a conditioned place preference (CPP) model of 
methamphetamine addiction. CPP uses the principles of associative learning to model seeking 
behaviour in animals, and therefore offers the ideal model to investigate the learning and 
memory aspects of addiction. We hypothesized that using a vasopressin V1b antagonist (SSR 
149415) and oxytocin as our treatments during the extinction phase of our 3 phase 
reinstatement model, the associative learnt neuroadaptations and behaviours associated with 
methamphetamine administration would be inhibited, resulting in a decreased tendency to 
relapse when faced with a priming dose of the drug.  
 
Our behavioural results in the acquisition phase showed that methamphetamine did induce 
place preference behaviour in some of our animals and an increase in the time spent in the 
drug-paired compartment when tested after the acquisition phase indicated seeking behaviour 
in the drug treated animals. Although CPP does display validity as an animal model of 
addiction, it has been found to show some unreliability due to various factors as outlined in 
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chapter 1. Possibly due to genotypic differences in rodents, there was a poor appearance of 
place preference in the methamphetamine group treated with saline, with only 3 out of 8 
animals showing a marked positive place preference and 1 spending nearly equal time in each 
compartment.  
 
Whilst this result does seem to reflect a failure of our addiction model in this group, it can be 
seen that each group receiving methamphetamine underwent the same procedure during the 
acquisition phase, and as such their results are comparable. Therefore, the significant positive 
CPP in the other two groups serves to support the validity of our model, and allows for the 
conclusion that variances among animals may occur in this model.  
 
Treatment with the vasopressin antagonist resulted in a reduction in seeking behaviour and 
the inhibition of primer-induced reinstatement in methamphetamine addicted animals. This 
reduction in seeking behaviour was evident from our behavioural data, where the significant 
decrease in time spent in the initial preferred side in response to methamphetamine treatment 
was lost, indicating an attenuation of drug seeking behaviour. The effect of vasopressin 
antagonism on the reinstatement of seeking behaviours was also evident from our behavioural 
data, with no increase in time spent in the drug-paired compartment being observed. 
 
Oxytocin treatment also seemed to show a tendency towards attenuating drug seeking 
behaviour, with time spent in the drug-paired compartment showing a definite, though not 
significant decrease. Interestingly, reinstatement times in the drug-paired compartment 
showed a marked increase when compared with post test 1, showing that oxytocin may tend 
to attenuate seeking behaviour, but was not effective in inhibiting reinstatement of seeking 
behaviour when presented with a priming dose of the drug.  
 
As an increase in dopamine release in response to methamphetamine is a known 
neurochemical effect, we evaluated the striatal levels of dopamine to determine if the 
neurobiological marker of addiction was present, and if oxytocin and the vasopressin 
antagonist had any effect on this. Our data showed an increase in striatal dopamine content 
following methamphetamine administration; however no changes in dopamine levels were 
seen in response to oxytocin or SSR 149415, indicating that their attenuating affects did not 




Within the learning and memory processes associated with addiction, CREB has been seen to 
play a vital role in the signalling cascades for long-term potentiation and memory formation, 
as well as being upregulated in response to repeated drug exposure (Mizuno et al., 2002; 
Chao et al., 2004). To examine the mechanism by which these addictive processes occurred, 
we evaluated CREB levels in the hippocampus of our animals using western blot analysis. 
However no significant differences in CREB levels were found between any of our 
experimental groups. 
 
In conclusion, it is well established that addiction shares many neural mechanisms with 
learning and memory, and that the development of addiction could be viewed as a case of 
inappropriate associative learning (Kopnisky and Hyman, 2002). Neuropeptides vasopressin 
and oxytocin have been implicated in the processes of learning and memory, although their 
exact roles in this regard are widely debated (Engelmann et al., 1996). Studies using these 
neuropeptides in the context of addiction have produced varying results, with no clear 
mechanism of action indicated as to how they affect the neural circuits implicated in 
addiction.  
Our study showed potential in indicating SSR 149 415 as a possible treatment in 
methamphetamine addicts as it both attenuated methamphetamine seeking in the extinction 
phase, as well as inhibited the reinstatement of drug seeking in response to a primer. We have 
also identified oxytocin as a possible treatment to aid in the extinction of drug seeking 
behaviour; however oxytocin fell short as it was not sufficient to overcome the reinforcing 
effects of a drug primer. This short fall could be, in part, due to the dose of oxytocin that was 
given. It has been hypothesized that neuropeptides can enter the brain in very small amounts, 
passing through the blood brain barrier when given subcutaneously (Kovács et al., 1998). At 
a dose of 1mg/kg, the amount of oxytocin actually reaching its brain target could therefore 
have been negligible. However, even with potentially minimal neural penetration, oxytocin 
did influence drug seeking behaviours after its administration during the period of ‘sobriety’.  
 
A recommendation for future studies would therefore be to administer the vasopressin 
antagonist and oxytocin in a dose-dependent manner, to establish whether higher doses may 
improve its efficay in attenuating drug seeking behaviour. It would also be useful to know 
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whether these treatment options are equally efficacious to the various drugs of abuse. A 
further refinement of the experimental 3 phase model of addiction would be to use only the 
animals that show strong positive place preference behaviour in phase 1, to minimise 
behavioural and neurochemical variability. In the present study data from all animals were 
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